

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Is exercise-based cardiac rehabilitation effective: re-examination of the evidence

Systematic review and meta-analysis

| | |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-019656 |
| Article Type: | Research |
| Date Submitted by the Author: | 18-Sep-2017 |
| Complete List of Authors: | Powell, Richard; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; University of Warwick, Warwick Clinical Trials Unit, Warwick Medical School, McGregor, Gordon; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; Coventry University, Faculty of Health and Life Sciences, Ennis, Stuart; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; Cardiff Metropolitan University, Cardiff Centre for Exercise & Health, Kimani, Peter; University of Warwick, Statistics and Epidemiology Unit, Warwick Medical School, Underwood, Martin; Warwick University, Warwick Clinical Trials Unit, Warwick Medical School, |
| Primary Subject Heading: | Rehabilitation medicine |
| Secondary Subject Heading: | Cardiovascular medicine, Evidence based practice |
| Keywords: | Coronary heart disease < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY, Myocardial infarction < CARDIOLOGY, REHABILITATION MEDICINE |
| | |

SCHOLARONE™
Manuscripts

Is exercise-based cardiac rehabilitation effective: re-examination of the evidence

Systematic review and meta-analysis

R Powell ^{1,5*}, G McGregor ^{1,2}, S Ennis ^{1,3}, P K Kimani ⁴, M Underwood ⁵

¹ Department of Cardiac Rehabilitation, Centre for Exercise & Health, University Hospital, Coventry, CV1 3LN, UK, ² Faculty of Health and Life Sciences, Coventry University, Coventry, CV1 5FB, UK, ³ Cardiff Centre for Exercise & Health, Cardiff Metropolitan University, Cardiff, CF5 2YB, UK ⁴ Statistics and Epidemiology Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK, ⁵ Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.

R Powell, Clinical Exercise Physiologist

G McGregor, Clinical Research Fellow

S Ennis, Clinical Exercise Physiologist

P K Kimani, Assistant Professor in Medical Statistics

M Underwood, Professor

*Correspondence to: Richard Powell, Richard.powell@uhcw.nhs.uk

Word count

3360 words

Abstract

Objectives

To determine the contemporary effectiveness of exercise-based CR.

Data sources

Studies included in, or meeting the entry criteria for the 2016 Cochrane review of exercise-based CR in patients with coronary artery disease.

Study eligibility criteria

Randomised controlled trials (RCTs) of exercise-based CR vs. a no exercise control whose participants were recruited after the year 2000.

Study appraisal and synthesis methods

Two separate reviewers independently screened the characteristics of studies. One reviewer quality appraised any new studies and assessed their risk of bias using the Cochrane Collaboration's recommended risk of bias tool. Data were reported as the risk difference (95% CI).

Results

We included 22 studies with 4,834 participants (mean age 59.5 years, 78.4% male). We found no differences in outcomes at their longest follow-up period for: all-cause mortality (19 studies; n=4,194; risk difference 0.00, 95% CI -0.02 to 0.01, p=0.38), cardiovascular mortality (9 studies; n= 1,182; risk difference -0.01, 95% CI -0.02 to 0.01, p=0.25) and hospital admissions (11 studies; n= 1,768; risk difference -0.05, 95% CI -0.10 to -0.00, p=0.05).

Conclusions and implications of key findings

These data do not support the continued use of exercise-based CR for secondary prevention in people with coronary artery disease.

Systematic review registration number

Prospero: International prospective register of systematic reviews. 2017. 42017073616.
Available from: https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017073616

Strengths and Limitations of this study

- To our knowledge, this is the first systematic review of exercise-based CR that has pooled data relevant to the current medical management of patients diagnosed with coronary artery disease.

- For analysis, we present the data as the risk difference (95% CI), which ensures all studies reporting data on the outcomes of interest were included.
- This systematic review pools data from studies that deliver an intervention recognised as best practice in exercise-based Cardiac Rehabilitation, where multiple approaches, including educational/psychosocial components, as well as the exercise component were used.
- We have not done a de novo quality assessment of 21/22 studies included in this review and instead rely on previous Cochrane assessment.
- We did not include health-related quality of life as an outcome measure as this unsuitable for meta-analysis.

Keywords

Coronary artery disease, exercise-based cardiac rehabilitation, all-cause mortality, cardiovascular mortality, hospital admissions.

Background

Cardiovascular disease is the world's biggest killer, accounting for 15 million deaths in 2015(1).

Secondary prevention of coronary artery disease through exercise-based CR in those who have a diagnosis of coronary artery disease has the potential to reduce mortality, reduce hospital admissions and increase quality of life. Guidelines internationally endorse the use of exercise-based CR programmes(2-5).

Typically, exercise-based CR aims to achieve 20-60 minutes of moderate intensity continuous exercise, 3-5 times a week, with muscular strength and endurance exercises prescribed in conjunction(6). Additionally, most programmes include supplementary education (coronary risk factors and cardiac misconceptions), advice on diet and access to psychological support to supplement the exercise training(2,4,7,8). Typically exercise-based CR is delivered in a supervised centre-based setting, although home-based programmes are used(9).

A 2016 Cochrane review (63 studies, n=14,486 participants) found benefits of exercise-based CR for patients with coronary artery disease. Both cardiovascular mortality (27 studies, RR 0.74, 95% CI 0.64 to 0.86) and hospital re-admissions were reduced (15 studies, RR 0.82, 95% CI 0.70 to 0.96), when compared to a no exercise control. However, in contrast to previous systematic reviews and meta-analyses, there was no reduction in risk of re-infarction (36 studies, RR 0.90, 95% CI 0.79 to 1.04) or all-cause mortality (47 studies, RR 0.96, 95% CI 0.88 to 1.04)(10).

Over recent decades, the medical management of coronary artery disease has been transformed. The introduction of primary percutaneous coronary intervention has reduced short-term major adverse cardiac events and increased long-term survival(11-14). Simultaneously, there have also been widespread

1 advances in secondary preventative medical therapy. This includes the introduction of aspirin and beta-
2 blockers in the 1980s(15,16), lipid-lowering statins and angiotensin converting enzyme inhibitors in the
3 1990s(17,18) and more recently, the introduction of clopidogrel, a secondary anti-platelet, in
4 2007(19,20). Age-adjusted mortality has decreased substantially in this population(21). Systematic
5 reviews and meta-analyses that include data from older studies may not correctly assess the potential
6 effect of exercise-based CR. We hypothesise that previous reviews have overestimated the potential
7 health gain from exercise-based CR.
8
9
10

11 **Objectives**

12
13
14
15
16 To determine the contemporary effectiveness of exercise-based CR on all-cause mortality,
17 cardiovascular mortality, and hospital readmissions in patients with coronary artery disease.
18

19 **Methods**

20 ***Search Strategy***

21
22
23 To identify relevant studies, we started with the latest Cochrane review of exercise-based CR in
24 patients with coronary artery disease(10). Studies identified as 'awaiting assessment' or 'on-going' in this
25 review were re-visited to establish whether publication had been reached. To identify any new studies
26 published since the completion of the Cochrane review, an updated search was run on the 28/2/2017.
27 This search used the same search strategies as the latest Cochrane review(10). We searched Cochrane
28 Central Register of Controlled Trials (CENTRAL) (*appendix 1*), MEDLINE (Ovid), EMBASE (Ovid) and
29 CINAHL (EBSCO) databases. This approach allowed us to efficiently identify all relevant studies. Where
30 appropriate, we contacted original authors for clarification of any new included studies.
31

32
33
34
35
36 Two separate reviewers (RP and GM) independently screened the characteristics of studies in
37 the latest Cochrane review, studies identified as 'awaiting assessment' or 'on-going' and studies
38 identified in the updated search. Full text publications were retrieved to allow for further examination
39 and to verify study inclusion. Any discrepancies were resolved by a third reviewer (MU).
40
41

42 ***Criteria for considering studies***

43
44
45 In 1996, The Task Force on the Management of Acute Myocardial Infarction of the European
46 Society of Cardiology first recommended early (within two hours) primary percutaneous interventions in
47 preference to thrombolytic therapy for acute myocardial infarction(22). Two years later, guidelines set by
48 the Joint British recommendations on prevention of Coronary Heart Disease in Clinical Practice were
49 published outlining the recommendations for best practice for secondary prevention medical
50 therapies(23). Although there have been some changes, notably the introduction of a second anti-platelet
51 agent in the early 2000s(19,20), the approach to secondary prevention medical therapies has not
52 changed since then. Allowing time for implementation of these guidelines and recommendations, we
53
54
55
56
57

1 identified and included studies whose participants were recruited after the year 2000, to represent a
2 contemporary population engaging in exercise-based CR.
3

4 Where there was no indication of recruitment period, the diagnosis and the secondary
5 preventative medical therapy received by participants included in the trial determined the inclusion or
6 exclusion of the study in the analysis.
7

8 9 ***Types of studies***

10
11 We included randomised controlled trials of exercise-based CR compared to a no exercise
12 control with a minimum follow-up period of six months. Data reported at the longest follow-up period
13 were included in the analysis.
14
15

16 17 ***Types of participants***

18
19 We used the same entry criterion as previous Cochrane reviews.
20

- 21
22 • People who have had a myocardial infarction, or who had undergone revascularisation
23 (coronary artery bypass grafting or percutaneous coronary intervention) or who have
24 angina pectoris or coronary artery disease defined by angiography.
25
26
- 27 • On optimal secondary preventative medical therapy.
28
29
- 30 • Recruited to hospital-based, community-based or home-based CR programmes.
31
32

33 34 ***Types of intervention(s)***

35
36 Randomised controlled trials consisted of supervised or non-supervised exercise-based CR. The
37 intervention was exercise alone or exercise as part of a comprehensive CR programme (consisting of
38 educational/psychosocial components). 'No exercise control' consisted of standard medical care,
39 including optimal secondary preventative medical therapy, education and advice about diet and exercise,
40 psychosocial support but with no formal exercise intervention.
41
42
43

44 45 ***Types of outcome measures***

46
47 We extracted data on: all-cause mortality, cardiovascular mortality and hospital re-admissions.
48 We did not include health-related quality of life as the authors of the 2016 Cochrane review found this
49 unsuitable for meta-analysis.
50
51

52 53 ***Data collection, statistical analysis and quality assessment***

54
55 We pooled data using Review Manager 5.3(24). Previous Cochrane reviews have presented the
56 data as individual and pooled risk ratio (95% CI). Using risk ratios automatically removed studies with
57

1 no events in either study arm from the analysis. Nine studies (n= 936 participants) reporting on all-
2 cause mortality, cardiovascular mortality or hospital re-admissions, were excluded from one or more
3 meta-analyses in the 2016 Cochrane review for this reason. We therefore present the data as the risk
4 difference (95% CI), which ensures all studies reporting data on the outcomes of interest were included.
5
6

7 We applied a random-effects model to all analyses given the clinical heterogeneity of individual
8 studies. Heterogeneity of included studies were tested statistically using the χ^2 test of heterogeneity and
9 I^2 statistic(25).
10

11 We did not repeat quality assurance checks already completed by the authors of the Cochrane
12 review. For separate study risk of bias breakdown for these studies, we refer the reader to the existing
13 *characteristics of studies*(10). For studies identified as 'awaiting assessment' or 'on-going' in the latest
14 Cochrane review, or in the updated search, we quality appraised these studies and assessed their risk of
15 bias using the Cochrane Collaboration's recommended risk of bias tool(26).
16
17
18
19
20
21

22 ***Assessment of risk of bias in additional included study***

23
24 One reviewer (RP) assessed the risk of bias in any additional included studies (*table 1*).
25 Assessment of three further quality domains as outlined in the latest Cochrane review was also
26 conducted (Groups balanced at baseline, Intention-to-treat analysis, Groups received comparable
27 treatment (except exercise)). A breakdown of the criteria used for assessing these three domains can be
28 found in the latest Cochrane review. Risk of bias assessments were checked by a second reviewer (GM)
29 and any discrepancies were resolved by a third reviewer (MU).
30
31
32
33

34 ***Patient Involvement***

35
36 No patients were involved in setting the objectives or outcome measures of this review, nor were
37 they involved in the design or implementation. No patients were involved in the analysis or
38 interpretation of the results, nor the writing of any drafts. There are no plans to disseminate the results
39 of the review to participants included in the studies of the review or any relevant patient networks.
40
41
42

43 **Results**

44 ***Studies retrieved***

45
46 Of the sixty-three studies included in the Cochrane review, twenty-one studies met our entry
47 criteria. We identified two additional relevant papers not included in the 2016 Cochrane review(27,28).
48 One was excluded because data for our specific research question were not available in a useable
49 format(27). In total, twenty-two studies (n=4,834 participants) contributed to the analysis. For the study
50 identified from the updated search(28), there was a low risk of bias in all eight domains, apart from the
51 intention-to-treat analysis, where there was no evidence of this analysis being conducted (*table 1*).
52
53
54
55
56
57
58
59
60

1 Three studies (3/22; 14%) reported on all three outcomes of interest, eleven studies (11/22; 50%)
2 reported on two outcomes of interest and eight studies (8/22; 36%) reported on one outcome of interest.

3 Two studies for all-cause mortality(29,30) and one study for cardiovascular mortality(29)
4 reported data at varying follow-up periods (6 to 12 months; >12 to 36 months; >3 years). Data from
5 these studies were taken at their longest follow-up period.
6
7

8 9 **Flow diagram**

10
11
12 (figure 1).
13

14 15 **Sample size, gender, age and study origin**

16
17 Of our twenty-two studies, ten studies were in Europe(28-37) and twelve from outside of
18 Europe(38-49). We included a total of 4,834 participants (3,788 (78.4%) males). Four studies included
19 males only(29,33,44,46) and one study included women only(50). Participants mean age was 59.5 years.
20 The mean age for individual studies ranged from 47.5 to 76.9 years (table 2).
21
22

23 24 **Incomplete outcome data**

25
26 The majority of trials (18/22; 82%) reported complete follow-up data, regardless of participants
27 who were lost to follow-up or who dropped out. In four studies, outcome data were incomplete for 75
28 (75/4,834; 1.6%) participants with no description of withdrawal or drop-out(40,46,47,49).
29
30

31 32 **Participant diagnosis of coronary artery disease and treatment received**

33
34 The diagnosis of participants recruited to the studies was described in the majority of studies
35 (21/22; 95%). Thirteen studies enrolled participants with mixed diagnoses, including angina pectoralis
36 or coronary artery disease defined by angiography, myocardial infarction, percutaneous coronary
37 interventions or coronary artery bypass grafts(31,35-41,43,45-47,49). Six studies enrolled participants
38 following acute myocardial infarction only(28,30,32,33,42,48) and two studies enrolled participants
39 diagnosed with angina pectoralis (unstable and stable angina) only(29,34). It was unclear from one
40 study whether participants following myocardial infarction were included and instead, the population
41 was defined as 'patients after coronary artery bypass graft surgery'(44) (table 2).
42
43

44 Six studies only recruited participants following percutaneous coronary intervention only(29,31,
45 32,34,40,45) and one study recruited participants following coronary artery bypass grafting only(44).
46 Twelve studies included participants who had received thrombolysis, percutaneous coronary
47 intervention, coronary artery bypass grafting and/or no revascularization procedure(30,35-39,41-
48 43,46,47,49). Three studies did not provide any breakdown of coronary intervention or surgical
49 procedure received by participants prior to enrollment(28,33,48) (table 2).
50
51

52 53 **Medication**

1 A full description and breakdown of the medication received by the participants, comparable to
2 optimal secondary prevention medical therapy defined by the Joint British recommendations on
3 prevention of Coronary Heart Disease in Clinical Practice set in 1998(23), was provided by 13/22 studies
4 (59%)(29-32,34-39,42,48,49). References to co-existing medical therapies were made in 7/22 (32%), but
5 no breakdowns were provided(28,33,40,41,44-46). One study referred to the prescription of anti-
6 hypertensive and hypolipidemic medications without reference to other recommended medications(47).
7 One study failed to provide any description or breakdown of co-existing medical therapies(43) (*table 2*).
8
9
10
11

12 ***Clearly defined recruitment period***

13
14
15 Seven studies (7/22; 32%) were explicit that they recruited participants after the year
16 2000(35,37,41,43-45,48). In three studies, participants were recruited either just before or during the
17 year 2000(29,30,40). Due to participant diagnosis, treatment received and co-existing medical
18 therapies, it was agreed by all reviewers to include these studies.
19

20 The remaining twelve studies failed to provide a recruitment period. Following further
21 examination of the full papers, due to adequate description of patient diagnosis, treatment received and
22 co-existing medical therapies, it was agreed by all reviewers to include these studies (*table 2*).
23
24

25 ***Content of the interventions***

26
27
28 The content of the interventions tested were heterogeneous in nature with multiple approaches
29 being adopted. Sixteen studies (16/22; 73%) compared exercise in combination with other therapies
30 (education, psychosocial management), whilst six studies compared exercise as a stand-alone
31 intervention, against a no exercise control. The exercise component alone varied considerably with
32 respect to setting, training modality, duration, session length, frequency and intensity (*table 3*).
33
34
35

36 ***Overall effects of interventions***

37 *All-cause mortality*

38
39
40
41 Nineteen studies (n=4,194 participants) reported all-cause mortality (*figure 2*). There was no
42 difference between groups at their longest follow-up (risk difference = 0.00, 95% CI -0.02 to 0.01,
43 p=0.38).
44
45

46 *Cardiovascular mortality*

47
48
49
50 Nine studies (n = 1,182 participants) reported cardiovascular mortality (*figure 3*). There was no
51 difference between groups at their longest follow-up (risk difference = -0.01, 95% CI -0.02 to 0.01,
52 p=0.25).
53
54

55 *Hospital admissions*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Eleven studies (n= 1,768 participants) reported on proportion with one or more hospital admissions (*figure 4*). There was a reduction of borderline statistical significance (risk difference = -0.05, 95% CI -0.10 to -0.00, p=0.05).

Discussion

The majority of interventions tested in the twenty-two trials (*table 3*) have delivered an intervention recognised as best practice in exercise-based CR, where multiple approaches, including educational/psychosocial components, as well as the exercise component were used(2,3,8).

Nevertheless, for all-cause mortality, the risk difference is 0.00 (95% CI -0.02 to 0.01). The largest trial included in our analysis, the UK-based Rehabilitation after myocardial infarction trial (RAMIT) trial, sought to show a 20% reduction in relative risk based on an 11% mortality; i.e. a 2.2% risk difference(30). The limits of the 95% confidence interval for the effect do not include the RAMIT trial's pre-specified clinically important difference. We therefore conclude that it is extremely unlikely that there is a worthwhile benefit from exercise-based CR on all-cause mortality. Furthermore, it is unlikely that any further trials of similar interventions, on similar populations, will change this conclusion.

Whilst no effect was seen on cardiovascular mortality, the limits of the 95% confidence intervals do not exclude a potential benefit. Any reduction in cardiovascular mortality is of very limited clinical relevance in the context of the overwhelming evidence of no effect on all-cause mortality.

These analyses however do not quite exclude a worthwhile effect on hospital admissions. Whilst the risk difference of -0.05 (95% CI -0.10 to -0.00) is of borderline statistical significance it is probably clinically unimportant in the context of no change on overall mortality.

We do not know, however, if there is a worthwhile benefit on quality of life. The authors of the 2016 Cochrane review reported some evidence for an improvement in quality of life in at least half of the sub-scales in four of the twenty-two studies we included that reported on differences in quality of life(31,44,45,48). Nevertheless, the largest included study (n=1813) found no differences at one year in any of the eight domains of the SF-36 or the three domains of the psychological general well-being score(30). This suggests that a worthwhile benefit on health-related quality of life, measured in this way, is very unlikely.

Five of the included papers in this review included a within trial health economic evaluation(29,39,42,43,49). Of these five papers, three studies showed no difference in healthcare costs between groups(39,42,49), one found healthcare costs to be lower for exercise-based CR(29), and one failed to report a p-value for cost difference(43). Based on these data, we are unable to comment on whether exercise-based CR might be cost-effective.

Based on health outcomes of all-cause mortality, cardiovascular mortality and rate of hospital admissions, the evidence in our review is insufficient to justify the use of exercise-based CR. It is for stakeholders to acknowledge these findings and decide whether outcomes of cardiorespiratory fitness, self-confidence, return to work and/or psychosocial outcomes should instead be the focus(3,7,51,52). Whether these 'softer' outcomes are enough to convince commissioners of health care services to continue to invest in CR interventions remains unknown.

Strengths and Limitations

1
2
3 To our knowledge, this is the first systematic review of exercise-based CR that has pooled data
4 relevant to the current medical management of patients diagnosed with coronary artery disease.
5 Although we have not done a de novo quality assessment of 21/22 studies included in this review and
6 instead relying on previous Cochrane assessment, it is unlikely we would have drawn different
7 conclusions from such an assessment(10).
8

9
10 Whilst there was no evidence of statistical heterogeneity across trials for all outcome measures
11 (P value < 0.01, I² >30%), there was substantial context and interventional heterogeneity. The studies
12 came from a wide range of clinical environments and countries, and the interventions delivered ranged
13 greatly in quality. When compared with both the BACPR ‘minimum standards and core components’(8)
14 and ACPICR guidelines(6) for the UK, there was considerable variation in the exercise component of the
15 interventions delivered (*table 3*). Critics have questioned the exercise component delivered and reported
16 in the RAMIT trial(30). They argued that under-dosage of exercise regarding the modality, intensity and
17 duration of training sessions led to its inconclusive result(53). Several other studies included in this
18 review fail to report on the intensity, modality and/or duration of the exercise component of the
19 interventions. Any benefits of exercise in patients with coronary artery disease are likely to be ‘dose-
20 dependent’(54). If patients engaging in exercise-based CR do not reach the correct dose of exercise, it is
21 unlikely that the physiological benefits will be achieved. It is a legitimate concern that participants in
22 many included trials are not receiving an adequate dose of exercise. Nevertheless, if in our data there
23 were sub-groups of participants who have received the correct dose and gained a worthwhile reduction
24 in mortality, there must be an equal number of participants in other sub-groups who had died because of
25 the intervention. This must be the case if the overall effect on mortality is zero.
26
27
28
29
30

31 32 **Conclusion**

33
34
35 Based on the outcomes of all-cause mortality, cardiovascular mortality and hospital admissions,
36 our analysis indicates conclusively that the current approach to exercise-based CR has no effect when
37 compared to a no exercise control.
38

39 If the provision of exercise-based CR is to continue in the UK, we recommend further research to
40 assess its impact on other outcomes and to assess cost-effectiveness. Alternatively, we recommend
41 different approaches to exercise which may include ‘high intensity interval training’(55). This may help
42 patients to achieve an adequate exercise ‘dose’ and ensure gains in cardiorespiratory fitness. We suggest
43 these interventions and outcomes should only be delivered and measured in the context of randomised
44 controlled trials.
45
46
47

48 **Contributors**

49
50
51 RP and MU were principally responsible for the study concept and design. RP and GM were
52 responsible for study selection, data extraction and risk of bias assessment. RP updated and ran the
53 searches. RP, MU and PK were responsible for statistical analysis and interpretation of data. GM and SE
54 provided clinical advice. RP and MU wrote the first draft of the review and all co-authors contributed to
55 review and editing of drafts of the report. All authors approved the final manuscript. RP is the study
56
57

1 guarantor and had full access to all trial level data in the review, takes responsibility for the integrity of
2 the data, and accuracy of the data analysis, and had final responsibility to submit for publication.

3 **Copyright**

4
5
6
7
8 The Corresponding Author has the right to grant on behalf of all authors and does grant on
9 behalf of all *authors*, a worldwide license to the Publishers and its licensees in perpetuity, in all forms,
10 formats and media (whether known now or created in the future), to i) publish, reproduce, distribute,
11 display and store the Contribution, ii) translate the Contribution into other languages, create
12 adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the
13 Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all
14 subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third
15 party material where-ever it may be located; and, vi) license any third party to do any or all of the above.

16 **Funding**

17
18
19
20 This review was not funded and hence no role was played by funders in the conception, data
21 synthesis, analysis, interpretation or in the drafting of the manuscript.

22 **Competing interests**

23
24
25
26 All authors have completed the *Unified Competing Interest form* (available on request from the
27 corresponding author) and declare: no support from any organisation for the submitted work; no
28 financial relationships with any organisations that might have an interest in the submitted work in the
29 previous three years, no other relationships or activities that could appear to have influenced the
30 submitted work.

31 **Ethical Approval**

32
33
34
35
36
37
38
39
40 Ethical approval not required.

41 **Data sharing**

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
No additional data available.

The lead author (RP) affirms that the manuscript is an honest, accurate, and transparent
account of the study being reported; that no important aspects of the study have been omitted; and that
any discrepancies from the study as planned and registered have been explained.

53 **Tables**

54 **Table 1. Risk of bias assessment for additional study**

Santaularia *et al.* 2017

| Bias | Authors' judgement | Support for judgement |
|--------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Low risk | A randomisation list in blocks of ten was created by a computer random number generator. The randomisation list and the allocation of patients to each group were independently controlled by the Clinical Trials Unit.' |
| Allocation concealment (selection bias) | Low risk | A randomisation list in blocks of ten was created by a computer random number generator. The randomisation list and the allocation of patients to each group were independently controlled by the Clinical Trials Unit.' |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk | An independent committee that was blind to the patients' treatment group assessed the main outcomes. This committee comprised a cardiologist, a rehabilitation cardiologist and a health information manager, all from different centres.' |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | There was no loss to follow-up. |
| Selective reporting (reporting bias) | Low risk | All outcomes described in the methods were reported in the results. Results regarding quality of life are presented in supplementary data but were not required for the current review. |
| Groups balanced at baseline | Low risk | No statistically significant differences in any baseline characteristics were observed between patients who agreed to participate and those who did not, except for age, which was higher in non-participants (65 vs. 60 years; $p = 0.006$) |
| Intention-to-treat analysis conducted | High risk | No |
| Groups received same treatment (apart from the intervention) | Low risk | Patients assigned to the control group received standard care given at the hospital'. In addition to standard care, patients randomised to the intervention group....'. |

Table 2. Overview of participants, recruitment period, patient diagnosis and medical therapy

| References, country | N | Mean age (years) | Male participants (%) | Recruitment period (years) | Patient diagnosis | Medication |
|------------------------------------------|---------|------------------|-----------------------|----------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aronov <i>et al.</i> (2010), Russia | 39 2 | 61.4 | 73.5 | None specified | AMI, stable angina, unstable angina or myocardial revascularisation. | Standard medical therapy- β -blocker, acetylsalicylic acid or other antithrombotic drug, nitrate, ACE inhibitor. Some patients on lipid-lowering drugs. |
| Belardinelli <i>et al.</i> (2001), Italy | 118 | 61 | 100 | None specified | CAD including AMI. Successful PCI in 1 or 2 native epicardial coronary arteries only. | According to international accepted protocols- aspirin, ticlopidine, calcium antagonists, nitrates. |
| Briffa <i>et al.</i> | 113 | 47.5 | 89.5 | None | Uncomplicated AMI or | Aspirin, antiarrhythmic agent, β - |

| | | | | | | | |
|----|--------------------|-----|------|------|--------------|-------------------------------|----------------------------------------------|
| 1 | (2005), | | | | specified. | recovery from unstable | blocker, ACE inhibitor, calcium |
| 2 | Australia | | | | | angina. PCI, CABG, | antagonist, long acting nitrate, |
| 3 | | | | | | thrombolytic therapy. | diuretic. |
| 4 | | | | | | | |
| 5 | Giallauria | | | | | | |
| 6 | <i>et al.</i> | | | | None | AMI and undergone | Aspirin, β -blocker, ACE inhibitor, |
| 7 | (2008), | 61 | 58.5 | 78.5 | specified. | primary or rescue PCI only. | ARB, statin. |
| 8 | Italy | | | | | | |
| 9 | Hambrech | | | | | | |
| 10 | <i>t et al.</i> | | | | | Stable CAD defined by | β -receptor antagonists, β -HMG- |
| 11 | (2004), | 101 | 56 | 87.3 | 1997-2001 | angina pectoralis and | CoA reductase inhibitors, ACE |
| 12 | Germany | | | | | amenable to PCI. AMI | inhibitor, acetylsalicylic acid. |
| 13 | | | | | | patients excluded. | |
| 14 | Higgins <i>et</i> | | | | | | Reference to medical therapy, only |
| 15 | <i>al.</i> (2001), | 105 | 60.8 | 81.3 | 1995-1997 | Post-PCI patients only. No | breakdown for lipid lowering |
| 16 | Australia | | | | | AMI 1 month pre-procedure. | medication. |
| 17 | | | | | | | |
| 18 | Houle <i>et</i> | | | | | Patients hospitalised for an | |
| 19 | <i>al.</i> (2012), | 65 | 51.5 | 100 | 2007-2008 | ACS (unstable angina, non- | Reference to medication in usual |
| 20 | Canada | | | | | ST-elevation or ST elevation | care group, but no breakdown. |
| 21 | | | | | | MI). PCI, CABG or no | |
| 22 | | | | | | revascularisation procedure. | |
| 23 | Kovoor <i>et</i> | | | | | | Aspirin, β -blocker, ACE inhibitor, |
| 24 | <i>al.</i> (2006), | 142 | 51.5 | 100 | None | AMI only. Thrombolytic | calcium channel blockers, nitrates, |
| 25 | Australia | | | | specified. | therapy, one patient in the | cholesterol-lowering agents, |
| 26 | | | | | | exercise treatment group | |
| 27 | | | | | | had primary angioplasty. | |
| 28 | Maddison | | | | | | |
| 29 | <i>et al.</i> | | | | | Diagnosis of IHD (angina, | No description. |
| 30 | (2014), | 171 | 59 | 20 | 2010-2012 | MI, revascularisation, | |
| 31 | New | | | | | including angioplasty, stent, | |
| 32 | Zealand | | | | | or CABG). | |
| 33 | | | | | | | |
| 34 | | | | | | | |
| 35 | Maroto <i>et</i> | | | | | (None | Medication regimens employed in |
| 36 | <i>al.</i> (2005), | 180 | 76.9 | 57.5 | specified) 2 | year | secondary prevention at discharge |
| 37 | Spain | | | | enrollment | period. | were clearly insufficient by standard |
| 38 | | | | | | AMI only. | criteria but currently meet Spanish |
| 39 | | | | | | | and European guidelines'. |
| 40 | Munk <i>et</i> | | | | | | |
| 41 | <i>al.</i> (2009), | 40 | 56.4 | 84.8 | None | Stable angina and unstable | Aspirin, β -blocker, ACE inhibitor, |
| 42 | Norway | | | | specified. | angina, post PCI only. AMI | ARB, statin, acetylsalicylic acid. |
| 43 | | | | | | patients excluded. | |
| 44 | Mutwalli | | | | | | |
| 45 | <i>et al.</i> | | | | | Undergone CABG surgery. | Participants received advice that |
| 46 | (2012), | 49 | 69.7 | 100 | 2008-2010 | Unknown whether AMI | focused on medications', no |
| 47 | Saudi | | | | | patients included. | breakdown. |
| 48 | Arabia | | | | | | |
| 49 | | | | | | | |
| 50 | | | | | | | |
| 51 | Oerkild <i>et</i> | | | | | Recent coronary event | β -blocker, antithrombotics, calcium |
| 52 | <i>al.</i> (2012), | 40 | 63.5 | 0 | 2007-2008 | defined as AMI, PCI, CABG | antagonists, lipid-lowering agents, |
| 53 | Denmark | | | | | or without invasive | diuretics. |
| 54 | | | | | | procedure. | |
| 55 | Reid <i>et al.</i> | | | | | | |
| 56 | (2012), | 22 | | | | ACS including AMI, | Reference to a 'descriptive summary |
| 57 | Canada | 3 | 54.5 | 87.3 | 2004-2007 | underwent successful PCI | in supplemental table', no access. |
| 58 | | | | | | only. | |
| 59 | | | | | | | |
| 60 | | | | | | | |
| 61 | Santaulari | | | | | | |
| 62 | <i>a et al.</i> | | | | | AMI only, no evidence of | Reference to cardiac medication, |
| 63 | (2017), | 85 | 59.6 | 84.7 | None | revascularisation procedure. | but no breakdown |
| 64 | Spain | | | | specified. | | |
| 65 | | | | | | | |
| 66 | Seki <i>et al.</i> | | | | | | Reference to 'lipid-lowering drugs |
| 67 | (2008), | 39 | 57.8 | 83.8 | None | AMI, PCI or CABG. | and other medications', no |
| 68 | Japan | | | | specified. | | breakdown. |

| | | | | | | |
|---------------------------------------|----------|------|------|-----------------|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Toobert <i>et al.</i> (2000), USA | 25 | 64.5 | 0 | None specified. | CAD defined as atherosclerosis, AMI, PCI or CABG. | Anti-hypertensive and hypolipidemic medications. |
| VHSG <i>et al.</i> (2003), Norway | 197 | 64 | 75.8 | None specified. | AMI, unstable angina pectoris or after PCI or CABG. | Aspirin, β -blocker, statin, ACE inhibitor, calcium antagonist, warfarin. |
| Wang <i>et al.</i> (2012), China | 160 | 67 | 63.5 | 2005-2007 | AMI only. | Anti-platelet, Nitrate, β -blocker, ACE inhibitor, calcium antagonist, statin. |
| West <i>et al.</i> (2012), UK | 181 3 | 51.9 | 93.9 | 1997-2000 | AMI only. | Aspirin, β -blocker, ACE inhibitor, diuretic, long acting nitrate/ calcium channel blocker, statin, GTN. |
| Yu <i>et al.</i> (2004), China | 26 9 | 56 | 83.9 | None specified. | Recent AMI, after elective PCI or thrombolytic therapy. | Anti-platelet, β -blocker, calcium channel blocker, nitrate, statin, ACE inhibitor, diuretic. |
| Zwisler <i>et al.</i> (2008), Denmark | 44 6 | 55.5 | 72.1 | 2000-2003 | AMI, angina pectoris or after PCI or CABG. | Antithrombotics, lipid-lowering drugs, β -blocker, calcium antagonists, ACE inhibitor, diuretic, long-acting nitrates. |

AMI- Acute Myocardial Infarction, CAD- Coronary Artery Disease, PCI- Percutaneous Coronary Intervention, IHD- Ischaemic Heart Disease, CABG- Coronary Artery Bypass Graft, CHD- Coronary Heart Disease, ACS- Acute Coronary Syndrome, ACE- Angiotensin-Converting-Enzyme, ARB- Angiotensin Receptor Blockers, GTN- Glyceryl Trinitrate.

Table 3. Overview of exercise interventions

| Reference s, country | Exercise Intervention | Modality | Study Duratio n | Session Duration/Frequency/Intensity | Additional |
|------------------------------------------|------------------------------------------------------------------------------|---------------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| | | | | | |
| Aronov <i>et al.</i> (2010), Russia | Moderate intensity physical training (unknown setting). | Cycle ergometer. | 12 months | 45 minutes- 60 minutes/ 3 sessions per week/ 50-60% of the performed capacity by bicycle ergometry. | None specified. |
| Belardinelli <i>et al.</i> (2001), Italy | Moderate intensity exercise (supervised in hospital gym). | Cycle ergometer. | 6 months | 53 minutes/ 3 sessions per week/ 60% of peak oxygen uptake (VO ₂ Peak). | None specified. |
| Briffa <i>et al.</i> (2005), Australia | Aerobic circuit training (supervised in hospital). | Aerobic circuit training. | 6 weeks | 60-90 minutes/ 3 sessions per week/ not specified. | Education and psychosocial counselling. |
| Giallauria <i>et al.</i> (2008), Italy | Moderate intensity exercise (supervised in centre). | Cycle ergometer. | 6 months | 40 minutes/ 3 sessions per week/ 60%-70% of peak oxygen uptake (VO ₂ Peak). | None specified. |
| Hambrecht <i>et al.</i> (2004), Germany | Moderate intensity exercise (supervised in hospital & unsupervised at home). | Cycle ergometer. | 12 months | 10 minutes- 42 sessions per week (hospital), 20 minutes- 7 sessions per week (home) plus 60 minutes' group training- 1 session per week/ 70% of symptom-limited max HR. | None specified. |
| Higgins <i>et al.</i> (2001), Australia | Moderate intensity walking programme (unsupervised at home). | Walking. | Not specified. | Not specified/ not specified/ not specified. | Psychologica l plus education. |

| | | | | | | |
|----|-----------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| 1 | | | | | | |
| 2 | Houle <i>et al.</i> | Pedometer-based walking programme (unsupervised at home). | Walking. | 12 months | Not specified/ not specified/ not specified. | Education plus socio-cognitive. |
| 3 | (2012), | | | | | |
| 4 | Canada | | | | | |
| 5 | | | | | | |
| 6 | Kovoor <i>et al.</i> (2006), | Standard Cardiac Rehabilitation programme (unknown setting). | Not specified. | 5 weeks | Not specified/ 2-4 sessions per week/ not specified. | Education and counselling |
| 7 | Australia | | | | | |
| 8 | | | | | | |
| 9 | | | | | | |
| 10 | Maddison <i>et al.</i> (2014), | Automated package of text messages to increase exercise behaviour (unsupervised at home). | Moderate to vigorous aerobic exercise e.g. walking and household chores. | 24 weeks | Minimum of 30 minutes/ at least 5 sessions per week/ not specified. | Optional access to other cardiac rehabilitation service or support. |
| 11 | New Zealand | | | | | |
| 12 | | | | | | |
| 13 | | | | | | |
| 14 | | | | | | |
| 15 | Maroto <i>et al.</i> (2005), | Individualised physical training (supervised in hospital gym). | Physiotherapy and aerobic training on mats or a cycle ergometer. | 3 months | 60 minutes/ 3 sessions per week/ 75-85% max HR. | Psychological, education plus return to work counselling. |
| 16 | Spain | | | | | |
| 17 | | | | | | |
| 18 | | | | | | |
| 19 | | | | | | |
| 20 | Munk <i>et al.</i> (2009), | Moderate/high intensity interval training (supervised in centre). | Cycle ergometer or running. | 6 months | 60 minutes/ 3 sessions per week/ 60-70% & 80-90% max HR. | Spine & abdominal resistance training. |
| 21 | Norway | | | | | |
| 22 | | | | | | |
| 23 | | | | | | |
| 24 | Mutwalli <i>et al.</i> (2012), | Moderate intensity walking programme (unsupervised at home). | Walking. | 6 months | 30 minutes/ 7 sessions per week/ not specified. | Education. |
| 25 | Saudi Arabia | | | | | |
| 26 | | | | | | |
| 27 | | | | | | |
| 28 | Oerkild <i>et al.</i> (2012), | Moderate intensity exercise (unsupervised at home). | Individualised | 12 months | 30 minutes/ 6 sessions per week/ 11-13 on the Borg Scale. | Risk factor management . |
| 29 | Denmark | | | | | |
| 30 | | | | | | |
| 31 | | | | | | |
| 32 | Reid <i>et al.</i> (2012), | Internet based physical activity plan and motivational tool to increase physical activity (unsupervised at home). | Not specified. | 20 weeks | Not specified/ not specified/ not specified. | None specified. |
| 33 | Canada | | | | | |
| 34 | | | | | | |
| 35 | | | | | | |
| 36 | | | | | | |
| 37 | | | | | | |
| 38 | | | | | | |
| 39 | Santaularia <i>et al.</i> (2017), | Outpatient exercise training programme (supervised in hospital). | Cycle ergometer | 10 weeks | 60 minutes/ 3 sessions per week/ 75-90% max HR (RPE 11-15 on Borg Scale) | Resistance training, education and risk factor management . |
| 40 | Spain | | | | | |
| 41 | | | | | | |
| 42 | | | | | | |
| 43 | | | | | | |
| 44 | Seki <i>et al.</i> (2008), | Moderate intensity aerobic exercise (supervised in centre & unsupervised at home). | Walking, cycle ergometer, jogging. | 6 months | 50-110 minutes- 1 session per week (centre), ≥ 30 minutes- 2 sessions per week (home)/ 12-13 on the standard Borg scale. | Education. |
| 45 | Japan | | | | | |
| 46 | | | | | | |
| 47 | | | | | | |
| 48 | Toobert <i>et al.</i> (2000), | Walking or aerobics (supervised in centre & unsupervised at home). | Walking or aerobics. | 24 months | 60 minutes- 7 sessions per week (centre), 60 minutes- 3 sessions per week (home)/ Individually prescribed. | Education and psychological support. |
| 49 | USA | | | | | |
| 50 | | | | | | |
| 51 | | | | | | |
| 52 | VHSG <i>et al.</i> (2003), | Dynamic endurance physical activity (supervised, group sessions in centre). | Dynamic endurance training. | 15 weeks | 55 minutes/ 2 sessions per week/ RPE 11-13 on the Borg Scale, increased to 13-15 after 6 weeks. | Education and psychological support. |
| 53 | Norway | | | | | |
| 54 | | | | | | |
| 55 | | | | | | |
| 56 | Wang <i>et al.</i> (2012), | Not specified. | Not specified. | Not specified. | Not specified/ not specified/ not specified. | Education. |
| 57 | China | | | | | |
| 58 | | | | | | |
| 59 | | | | | | |
| 60 | | | | | | |

| | | | | | |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| West <i>et al.</i> (2012), UK | Not specified, multi-centre (supervised in centre). | Varied by centre (exercise equipment in physiotherapy gyms). | 6-8 weeks | Averaged 20 hours over 6-8 weeks/ 1-2 sessions per week/ not specified. | Education plus psychological support. |
| Yu <i>et al.</i> (2004), China | Ambulatory and aerobic cardiovascular training (supervised in hospital and centre, unsupervised at home). | Walking, treadmill, cycle ergometry, rowing, stepper, arm ergometry, dumbbell. | 8 1/2 months | 2 hours/ 2 sessions per week (centre), not specified (home)/ 65-85% of maximal aerobic capacity (VO ₂ Peak). | Resistance training and education. |
| Zwisler <i>et al.</i> (2008), Denmark | Intensive CR programme (supervised in centre). | Not specified. | 6 weeks | Not specified/ 2 sessions per week/ not specified. | Education and psychosocial support. |

HR- Heart Rate, VO₂ Peak- Peak Oxygen Uptake

References

- World Health Organisation. Top 10 causes of death worldwide- Fact Sheet 2017. Date accessed- 29/05/2017. Available from: <http://www.who.int/mediacentre/factsheets/fs310/en/>.
- NICE. Myocardial Infarction: cardiac rehabilitation and prevention of further cardiovascular disease. 2013. Date accessed- 31/05/2017. Available from: <https://www.nice.org.uk/guidance/cg172/resources/myocardial-infarction-cardiac-rehabilitation-and-prevention-of-further-cardiovascular-disease-pdf-35109748874437>.
- BACPR. Cardiovascular Disease Prevention and Rehabilitation. 2012. Date accessed- 31/05/2017. Available from: http://www.bacpr.com/resources/46C_BACPR_Standards_and_Core_Components_2012.pdf.
- Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. *Eur J Prev Cardiol.* 2014;21(6):664-81.
- Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. *J Cardiopulm Rehabil Prev.* 2007;27(3):121-9.
- ACPICR. Standards for Physical Activity and Exercise in the Cardiovascular Population. 2015. Date accessed- 31/05/2017. Available from: http://acpicr.com/sites/default/files/ACPICR_Standards_2015.pdf.
- Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. *BMJ.* 2015;351:h5000.
- Buckley JP, Furze G, Doherty P, Speck L, Connolly S, Hinton S, et al. BACPR scientific statement: British standards and core components for cardiovascular disease prevention and rehabilitation. *Heart.* 2013;99(15):1069-71.
- Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. *BMJ.* 2010;340:b5631.
- Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. *J Am Coll Cardiol.* 2016;67(1):1-12.
- Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet.* 2003;361(9351):13-20.
- D'Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary angioplasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis. *Eur Heart J.* 2011;32(8):972-82.

13. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J.* 2003;24(1):28-66.
14. West RM, Cattle BA, Bouyssie M, Squire I, de Belder M, Fox KA, et al. Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. *Eur Heart J.* 2011;32(6):706-11.
15. Anon. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Multicentre international study: supplementary report. *Br Med J.* 1977;2(6084):419-21.
16. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. *Br Med J.* 1974;1(5905):436-40.
17. Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344(8934):1383-9.
18. Anon. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. *Circulation.* 1998;97(22):2202-12.
19. Skinner JS, Minhas R. Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction. *Heart.* 2007;93(7):864-6.
20. Eisen A, Bhatt DL. Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. *Heart.* 2016.
21. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. *Curr Probl Cardiol.* 2010;35(2):72-115.
22. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J.* 1996;17(1):43-63.
23. Wood DA DP, Poutler N, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. *Heart.* 1998;80 Suppl 2:S1-29.
24. RevMan. The Nordic Cochrane Centre: The Cochrane Collaboration, version 5.3 (Review Manager)2014.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327(7414):557-60.
26. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
27. Kadda O, Kotanidou A, Manginas A, Stavridis G, Nanas S, Panagiotakos DB. Lifestyle intervention and one-year prognosis of patients following open heart surgery: a randomised clinical trial. *Journal of Clinical Nursing.* 2015;24(11-12):1611-21.
28. Santaularia N, Caminal J, Arnau A, Perramon M, Montesinos J, Abenoza Guardiola M, et al. The efficacy of a supervised exercise training programme on readmission rates in patients with myocardial ischemia: Results from a randomised controlled trial. *European Journal of Cardiovascular Nursing.* 2017;16(3):201-12.
29. Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation.* 2004;109(11):1371-8.
30. West RR, Jones DA, Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. *Heart.* 2012;98(8):637-44.
31. Belardinelli R, Paolini I, Cianci G, Piva R, Georgiou D, Purcaro A. Exercise training intervention after coronary angioplasty: the ETICA trial. *J Am Coll Cardiol.* 2001;37(7):1891-900.
32. Giallauria F, Cirillo P, Lucci R, Pacileo M, De Lorenzo A, D'Agostino M, et al. Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. *Eur J Cardiovasc Prev Rehabil.* 2008;15(1):113-8.
33. Maroto JM, Artigao Ramirez R, Morales Durán MD, de Pablo Zarzosa C, Abreira V. [Cardiac rehabilitation in patients with myocardial infarction: a 10-year follow-up study]. *Rev Esp Cardiol.* 2005;58(10):1181-7.
34. Munk PS, Staal EM, Butt N, Isaksen K, Larsen AI. High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation A randomized controlled trial evaluating the relationship to endothelial function and inflammation. *Am Heart J.* 2009;158(5):734-41.
35. Oerkild B, Frederiksen M, Hansen JF, Prescott E. Home-based cardiac rehabilitation is an attractive alternative to no cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial. *BMJ Open.* 2012;2(6).

36. Vestfold Heartcare Study Group. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. *Eur J Cardiovasc Prev Rehabil.* 2003;10(6):429-37.
37. Zwisler AD, Soja AM, Rasmussen S, Frederiksen M, Abedini S, Abadini S, et al. Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial. *Am Heart J.* 2008;155(6):1106-13.
38. Aronov DM, Krasnitskii VB, Bubnova MG, Pozdniakov IM, Ioseliani DG, Shchegol'kov AN, et al. [Physical training at ambulatory-polyclinical stage in complex rehabilitation and secondary prevention of patients with ischemic heart disease after acute incidents. Effect on physical working capacity, hemodynamics, blood lipids, clinical course and prognosis (Russian cooperative study)]. *Kardiologiya.* 2009;49(3):49-56.
39. Briffa TG, Eckermann SD, Griffiths AD, Harris PJ, Heath MR, Freedman SB, et al. Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. *Med J Aust.* 2005;183(9):450-5.
40. Higgins HC, Hayes RL, McKenna KT. Rehabilitation outcomes following percutaneous coronary interventions (PCI). *Patient Educ Couns.* 2001;43(3):219-30.
41. Houle J, Doyon O, Vadeboncoeur N, Turbide G, Diaz A, Poirier P. Effectiveness of a pedometer-based program using a socio-cognitive intervention on physical activity and quality of life in a setting of cardiac rehabilitation. *Can J Cardiol.* 2012;28(1):27-32.
42. Kovoov P, Lee AK, Carrozzi F, Wiseman V, Byth K, Zecchin R, et al. Return to full normal activities including work at two weeks after acute myocardial infarction. *Am J Cardiol.* 2006;97(7):952-8.
43. Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr A, Jiang Y, et al. A mobile phone intervention increases physical activity in people with cardiovascular disease: Results from the HEART randomized controlled trial. *Eur J Prev Cardiol.* 2014;22(6):701-9.
44. Mutwalli HA, Fallows SJ, Arnous AA, Zamzami MS. Randomized controlled evaluation shows the effectiveness of a home-based cardiac rehabilitation program. *Saudi Med J.* 2012;33(2):152-9.
45. Reid RD, Morrin LI, Beaton LJ, Papadakis S, Kocourek J, McDonnell L, et al. Randomized trial of an internet-based computer-tailored expert system for physical activity in patients with heart disease. *Eur J Prev Cardiol.* 2012;19(6):1357-64.
46. Seki E, Watanabe Y, Shimada K, Sunayama S, Onishi T, Kawakami K, et al. Effects of a phase III cardiac rehabilitation program on physical status and lipid profiles in elderly patients with coronary artery disease: Juntendo Cardiac Rehabilitation Program (J-CARP). *Circ J.* 2008;72(8):1230-4.
47. Toobert DJ, Glasgow RE, Radcliffe JL. Physiologic and related behavioral outcomes from the Women's Lifestyle Heart Trial. *Ann Behav Med.* 2000;22(1):1-9.
48. Wang W, Chair SY, Thompson DR, Twinn SF. Effects of home-based rehabilitation on health-related quality of life and psychological status in Chinese patients recovering from acute myocardial infarction. *Heart Lung.* 2012;41(1):15-25.
49. Yu CM, Lau CP, Chau J, McGhee S, Kong SL, Cheung BM, et al. A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention. *Arch Phys Med Rehabil.* 2004;85(12):1915-22.
50. Toobert DJ, Strycker LA, Glasgow RE. Lifestyle change in women with coronary heart disease: what do we know? *J Womens Health.* 1998;7(6):685-99.
51. Valkeinen H, Aaltonen S, Kujala UM. Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis. *Scand J Med Sci Sports.* 2010;20(4):545-55.
52. Yohannes AM, Doherty P, Bundy C, Yalfani A. The long-term benefits of cardiac rehabilitation on depression, anxiety, physical activity and quality of life. *J Clin Nurs.* 2010;19(19-20):2806-13.
53. Conraads VM, Denollet J, De Maeyer C, Van Craenenbroeck E, Verheyen J, Beckers P. Exercise training as an essential component of cardiac rehabilitation. *Heart.* 2012;98(8):674-5; author reply 5.
54. Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. *Circulation.* 2011;124(7):789-95.
55. McGregor G, Nichols S, Hamborg T, Bryning L, Tudor-Edwards R, Markland D, et al. High-intensity interval training versus moderate-intensity steady-state training in UK cardiac rehabilitation programmes (HIIT or MISS UK): study protocol for a multicentre randomised controlled trial and economic evaluation. *BMJ Open.* 2016;6(11):e012843.

Legends

Figure 1. Summary of study selection process

Figure 2. All-cause mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR-Cardiac Rehabilitation.

1 *Figure 3.* Cardiovascular mortality for studies at their longest follow-up period. Filled squares represent the risk difference for
2 individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent
3 their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects
4 analysis. CR- Cardiac Rehabilitation.

5 *Figure 4.* Hospital admissions for studies at their longest follow-up period. Filled squares represent the risk difference for
6 individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent
7 their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects
8 analysis. CR- Cardiac Rehabilitation.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. Summary of study selection process

338x190mm (54 x 54 DPI)

Review only




Figure 2. All-cause mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)




Figure 3. Cardiovascular mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)




Figure 4. Hospital admissions for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 3 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 2 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4,5 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4/appendix 1 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4,5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 4,5 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 4,5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 5 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis. | 5 |



PRISMA 2009 Checklist

Page 1 of 2

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 5,6 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 6 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 12-15 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 5, 11,12 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 8 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 8/figures 2,3,4 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 11,12 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 8,9 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 9,10 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 10 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 11 |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Is exercise-based cardiac rehabilitation effective: a systematic review and meta-analysis

| | |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-019656.R1 |
| Article Type: | Research |
| Date Submitted by the Author: | 01-Dec-2017 |
| Complete List of Authors: | Powell, Richard; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; University of Warwick, Warwick Clinical Trials Unit, Warwick Medical School, McGregor, Gordon; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; Coventry University, Faculty of Health and Life Sciences, Ennis, Stuart; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; Cardiff Metropolitan University, Cardiff Centre for Exercise & Health, Kimani, Peter; University of Warwick, Statistics and Epidemiology Unit, Warwick Medical School, Underwood, Martin; Warwick University, Warwick Clinical Trials Unit, Warwick Medical School, |
| Primary Subject Heading: | Rehabilitation medicine |
| Secondary Subject Heading: | Cardiovascular medicine, Evidence based practice |
| Keywords: | Coronary heart disease < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY, Myocardial infarction < CARDIOLOGY, REHABILITATION MEDICINE |
| | |

SCHOLARONE™
Manuscripts

Is exercise-based cardiac rehabilitation effective: a systematic review and meta-analysis

R Powell ^{1,5*}, G McGregor ^{1,2}, S Ennis ^{1,3}, P K Kimani ⁴, M Underwood ⁵

¹ Department of Cardiac Rehabilitation, Centre for Exercise & Health, University Hospital, Coventry, CV1 3LN, UK, ² Faculty of Health and Life Sciences, Coventry University, Coventry, CV1 5FB, UK, ³ Cardiff Centre for Exercise & Health, Cardiff Metropolitan University, Cardiff, CF5 2YB, UK ⁴ Statistics and Epidemiology Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK, ⁵ Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.

R Powell, Clinical Exercise Physiologist

G McGregor, Clinical Research Fellow

S Ennis, Clinical Exercise Physiologist

P K Kimani, Assistant Professor in Medical Statistics

M Underwood, Professor

*Correspondence to: Richard Powell, Richard.powell@uhcw.nhs.uk

Word count

3716 words

Abstract

Objectives

To determine the contemporary effectiveness of exercise-based Cardiac Rehabilitation (CR).

Data sources

Studies included in, or meeting the entry criteria for the 2016 Cochrane review of exercise-based CR in patients with coronary artery disease.

Study eligibility criteria

Randomised controlled trials (RCTs) of exercise-based CR vs. a no exercise control whose participants were recruited after the year 2000.

Study appraisal and synthesis methods

Two separate reviewers independently screened the characteristics of studies. One reviewer quality appraised any new studies and assessed their risk of bias using the Cochrane Collaboration's recommended risk of bias tool. Data were reported as the risk difference (95% CI).

Results

We included 22 studies with 4,834 participants (mean age 59.5 years. 78.4% male). We found no differences in outcomes between exercise-based CR and a no exercise control at their longest follow-up period for: all-cause mortality (19 studies; n=4,194; risk difference 0.00, 95% CI -0.02 to 0.01, p=0.38) or cardiovascular mortality (9 studies; n = 1,182; risk difference -0.01, 95% CI -0.02 to 0.01, p=0.25). We found a small reduction in hospital admissions of borderline statistical significance (11 studies; n= 1,768; risk difference -0.05, 95% CI -0.10 to -0.00, p=0.05).

Conclusions and implications of key findings

Our analysis indicates conclusively that the current approach to exercise-based CR has no effect on all-cause mortality or cardiovascular mortality, when compared to a no exercise control. There may be a small reduction in hospital admissions following exercise-based CR that is unlikely to be clinically important.

Systematic review registration number

Prospero: International prospective register of systematic reviews. 2017. 42017073616.
Available from: https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017073616

Strengths and Limitations of this study

- To our knowledge, this is the first systematic review of exercise-based CR that has pooled data relevant to the current medical management of patients diagnosed with coronary artery disease.
- For analysis, we present the data as the risk difference (95% CI), which ensures all studies reporting data on the outcomes of interest were included.
- This systematic review pools data from studies that deliver an intervention recognised as best practice in exercise-based CR, where multiple approaches, including educational/psychosocial components, as well as the exercise component were used.
- We have not done a de novo quality assessment of 21/22 studies included in this review and instead rely on a previous Cochrane assessment.
- We did not include health-related quality of life as an outcome measure as this is unsuitable for meta-analysis.

Keywords

Coronary artery disease, exercise-based cardiac rehabilitation, all-cause mortality, cardiovascular mortality, hospital admissions.

Background

Cardiovascular disease is the world's biggest killer, accounting for 15 million deaths in 2015(1).

Secondary prevention of coronary artery disease through exercise-based CR in those who have a diagnosis of coronary artery disease, has the potential to reduce mortality, reduce hospital admissions and increase quality of life. Guidelines internationally endorse the use of exercise-based CR programmes(2-5).

Typically, exercise-based CR aims to achieve 20-60 minutes of moderate intensity continuous exercise, 3-5 times a week, with muscular strength and endurance exercises prescribed in conjunction(6). Additionally, most programmes include supplementary education (coronary risk factors and cardiac misconceptions), advice on diet and access to psychological support(2, 4, 7, 8). Typically exercise-based CR is delivered in a supervised centre-based setting, although home-based programmes are used(9).

A 2016 Cochrane review (63 studies, n=14,486 participants) found benefits of exercise-based CR for patients with coronary artery disease. Both cardiovascular mortality (27 studies, RR 0.74, 95% CI 0.64 to 0.86) and hospital re-admissions were reduced (15 studies, RR 0.82, 95% CI 0.70 to 0.96), when compared to a no exercise control. However, in contrast to previous systematic reviews and meta-

1 analyses, there was no significant reduction in risk of re-infarction (36 studies, RR 0.90, 95% CI 0.79 to
2 1.04) or all-cause mortality (47 studies, RR 0.96, 95% CI 0.88 to 1.04)(10).

3
4 Over recent decades, the medical management of coronary artery disease has been transformed.
5 The introduction of primary percutaneous coronary intervention has reduced short-term major adverse
6 cardiac events and increased long-term survival(11-14). Simultaneously, there have also been widespread
7 advances in secondary preventative medical therapy. This includes the introduction of aspirin and beta-
8 blockers in the 1980s(15, 16), lipid-lowering statins and angiotensin converting enzyme inhibitors in the
9 1990s(17, 18) and more recently, the introduction of clopidogrel, a secondary anti-platelet, in 2007(19,
10 20). Age-adjusted mortality has decreased substantially in this population(21). Systematic reviews and
11 meta-analyses that include data from older studies may not correctly assess the potential effect of
12 exercise-based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
13 based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
14 based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
15 based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
16 based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
17 based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
18 based CR.

19 **Objectives**

20
21
22 To determine the contemporary effectiveness of exercise-based CR on all-cause mortality,
23 cardiovascular mortality, and hospital readmissions in patients with coronary artery disease.

24 **Methods**

25
26 We conducted and reported this meta-analysis in accordance with PRISMA (Preferred Reporting
27 Items for Systematic Reviews and Meta-Analyses)(22).

28 ***Search Strategy***

29
30 To identify relevant studies, we started with the latest Cochrane review of exercise-based CR in
31 patients with coronary artery disease(10). Studies identified as 'awaiting assessment' or 'on-going' in this
32 review were re-visited to establish whether publication had been reached. To identify any new studies
33 published since the completion of the Cochrane review, an updated search was run on the 28/2/2017.
34 This search used the same search strategies as the latest Cochrane review(10). We searched Cochrane
35 Central Register of Controlled Trials (CENTRAL) (*appendix 1*), MEDLINE (Ovid), EMBASE (Ovid) and
36 CINAHL (EBSCO) databases. This approach allowed us to efficiently identify all relevant studies. Where
37 appropriate, we contacted original authors for clarification of any new included studies.

38
39 Two separate reviewers (RP and GM) independently screened the characteristics of studies in
40 the latest Cochrane review, studies identified as 'awaiting assessment' or 'on-going' and studies
41 identified in the updated search. Full text publications were retrieved to allow for further examination
42 and to verify study inclusion. Any discrepancies were resolved by a third reviewer (MU).

43 ***Criteria for considering studies***

1
2
3 In 1996, The Task Force on the Management of Acute Myocardial Infarction of the European
4 Society of Cardiology first recommended early (within two hours) primary percutaneous interventions in
5 preference to thrombolytic therapy for acute myocardial infarction(23). Two years later, guidelines set by
6 the Joint British recommendations on prevention of Coronary Heart Disease in Clinical Practice were
7 published outlining the recommendations for best practice for secondary prevention medical
8 therapies(24). Although there have been some changes, notably the introduction of a second anti-platelet
9 agent in the early 2000s(19, 20), the approach to secondary prevention medical therapies has not
10 changed since then. Allowing time for implementation of these guidelines and recommendations, we
11 identified and included studies whose participants were recruited after the year 2000, to represent a
12 contemporary population engaging in exercise-based CR.
13
14
15

16 Where there was no indication of recruitment period, the diagnosis and the secondary
17 preventative medical therapy received by participants included in the trial determined the inclusion or
18 exclusion of the study in the analysis.
19
20

21 ***Types of studies***

22
23
24 We included randomised controlled trials of exercise-based CR compared to a no exercise
25 control with a minimum follow-up period of six months. Data reported at the longest follow-up period
26 were included in the analysis.
27
28

29 ***Types of participants***

30
31
32 We used the same entry criterion as previous Cochrane reviews.
33
34

- 35 • People who have had a myocardial infarction, or who had undergone revascularisation
36 (coronary artery bypass grafting or percutaneous coronary intervention) or who have
37 angina pectoris or coronary artery disease defined by angiography.
38
39
- 40 • On optimal secondary preventative medical therapy defined by the Joint British
41 recommendations on prevention of Coronary Heart Disease in Clinical Practice(24).
42
43
- 44 • Recruited to hospital-based, community-based or home-based CR programmes.
45
46

47 ***Types of intervention(s)***

48
49
50 Randomised controlled trials consisted of supervised or non-supervised exercise-based CR. The
51 intervention was exercise alone or exercise as part of a comprehensive CR programme (consisting of
52 educational/psychosocial components). 'No exercise control' consisted of standard medical care,
53 including optimal secondary preventative medical therapy, education and advice about diet and exercise,
54 psychosocial support but with no formal exercise intervention.
55
56
57

Types of outcome measures

We extracted data on: all-cause mortality, cardiovascular mortality and hospital re-admissions. We did not include health-related quality of life as the authors of the 2016 Cochrane review found this unsuitable for meta-analysis.

Data collection, statistical analysis and quality assessment

We pooled data using Review Manager 5.3(25). Previous Cochrane reviews have presented the data as individual and pooled risk ratio (95% CI). Using risk ratios automatically removed studies with no events in either study arm from the analysis. Nine studies (n= 936 participants) reporting on all-cause mortality, cardiovascular mortality or hospital re-admissions, were excluded from one or more meta-analyses in the 2016 Cochrane review for this reason. We therefore present the data as the risk difference (95% CI), which ensures all studies reporting data on the outcomes of interest were included.

We applied a random-effects model to all analyses given the clinical heterogeneity of individual studies. Heterogeneity of included studies were tested statistically using the χ^2 test of heterogeneity and I^2 statistic(26).

We did not repeat quality assurance checks already completed by the authors of the Cochrane review. For separate study risk of bias breakdown for these studies, we refer the reader to the existing *characteristics of studies*(10). For studies identified as 'awaiting assessment' or 'on-going' in the latest Cochrane review, or in the updated search, we quality appraised these studies and assessed their risk of bias using the Cochrane Collaboration's recommended risk of bias tool(27).

Assessment of risk of bias in additional included study

One reviewer (RP) assessed the risk of bias in any additional included studies (*table 1*). Assessment of three further quality domains as outlined in the latest Cochrane review was also conducted (Groups balanced at baseline, Intention-to-treat analysis, Groups received comparable treatment (except exercise)). A breakdown of the criteria used for assessing these three domains can be found in the latest Cochrane review. Risk of bias assessments were checked by a second reviewer (GM) and any discrepancies were resolved by a third reviewer (MU).

Patient Involvement

No patients were involved in setting the objectives or outcome measures of this review, nor were they involved in the design or implementation. No patients were involved in the analysis or interpretation of the results, nor the writing of any drafts. There are no plans to disseminate the results of the review to participants included in the studies of the review or any relevant patient networks.

Results

Studies retrieved

Of the sixty-three studies included in the Cochrane review, twenty-one studies met our entry criteria. We identified two additional relevant papers not included in the 2016 Cochrane review(28, 29). One was excluded because data for our specific research question were not available in a useable format(28). In total, twenty-two studies (n=4,834 participants) contributed to the analysis (*figure 1*). For the study identified from the updated search(29), there was a low risk of bias in all eight domains, apart from the intention-to-treat analysis, where there was no evidence of this analysis being conducted (*table 1*).

Three studies (3/22; 14%) reported on all three outcomes of interest, eleven studies (11/22; 50%) reported on two outcomes of interest and eight studies (8/22; 36%) reported on one outcome of interest.

Two studies for all-cause mortality(30, 31) and one study for cardiovascular mortality(30) reported data at varying follow-up periods (6 to 12 months; >12 to 36 months; >3 years). Data from these studies were taken at their longest follow-up period. Mean maximum follow-up period was 24.7 months. Maximum follow-up period ranged from 24 weeks to 10 years (*table 2*).

Flow diagram

(*figure 1*).

Sample size, gender, age and study origin

Of our twenty-two studies, ten studies were in Europe(29-38) and twelve from outside of Europe(39-50). We included a total of 4,834 participants (3,788 (78.4%) males). Four studies included males only(30, 34, 45, 47) and one study included women only(51). Participants mean age was 59.5 years. The mean age for individual studies ranged from 47.5 to 76.9 years (*table 2*).

Incomplete outcome data

The majority of trials (18/22; 82%) reported complete follow-up data, regardless of participants who were lost to follow-up or who dropped out. In four studies, outcome data were incomplete for 75 (75/4,834; 1.6%) participants with no description of withdrawal or drop-out(41, 47, 48, 50).

Participant diagnosis of coronary artery disease and treatment received

The diagnosis of participants recruited to the studies was described in the majority of studies (21/22; 95%). Thirteen studies enrolled participants with mixed diagnoses, including angina pectoralis or coronary artery disease defined by angiography, myocardial infarction, percutaneous coronary interventions or coronary artery bypass grafts(32, 36-42, 44, 46-48, 50). Six studies enrolled participants following acute myocardial infarction only(29, 31, 33, 34, 43, 49) and two studies enrolled

1 participants diagnosed with angina pectoralis (unstable and stable angina) only(30, 35). It was unclear
2 from one study whether participants following myocardial infarction were included and instead, the
3 population was defined as ‘patients after coronary artery bypass graft surgery’(45) (*table 2*).

4
5 Six studies recruited participants following percutaneous coronary intervention only(30, 32, 33,
6 35, 41, 46) and one study recruited participants following coronary artery bypass grafting only(45).
7 Twelve studies included participants who had received thrombolysis, percutaneous coronary
8 intervention, coronary artery bypass grafting and/or no revascularization procedure(31, 36-40, 42-44,
9 47, 48, 50). Three studies did not provide any breakdown of coronary intervention or surgical procedure
10 received by participants prior to enrollment(29, 34, 49) (*table 2*).

14 15 **Medication**

16
17 A full description and breakdown of the medication received by the participants, comparable to
18 optimal secondary prevention medical therapy defined by the Joint British recommendations on
19 prevention of Coronary Heart Disease in Clinical Practice set in 1998(24), was provided by 13/22 studies
20 (59%)(30-33, 35-40, 43, 49, 50). References to co-existing medical therapies were made in 7/22 (32%),
21 but no breakdowns were provided(29, 34, 41, 42, 45-47). One study referred to the prescription of anti-
22 hypertensive and hypolipidemic medications without reference to other recommended medications(48).
23 One study failed to provide any description or breakdown of co-existing medical therapies(44) (*table 2*).

27 28 **Clearly defined recruitment period**

29
30 Seven studies (7/22; 32%) were explicit that they recruited participants after the year 2000(36,
31 38, 42, 44-46, 49). In three studies, participants were recruited either just before or during the year
32 2000(30, 31, 41). Due to participant diagnosis, treatment received and co-existing medical therapies, it
33 was agreed by all reviewers to include these studies.

34
35 The remaining twelve studies failed to provide a recruitment period. Following further
36 examination of the full papers, due to adequate description of patient diagnosis, treatment received and
37 co-existing medical therapies, it was agreed by all reviewers to include these studies (*table 2*).

40 41 **Content of the interventions**

42
43 The content of the interventions tested was heterogeneous with multiple approaches being
44 adopted. Sixteen studies (16/22; 73%) compared exercise in combination with other therapies
45 (education, psychosocial management), whilst six studies compared exercise as a stand-alone
46 intervention, against a no exercise control. The exercise component alone varied considerably with
47 respect to setting, training modality, duration, session length, frequency and intensity (*table 3*).

51 52 **Overall effects of interventions**

53 54 *All-cause mortality*

1 Nineteen studies (n=4,194 participants) reported all-cause mortality (*figure 2*). There was no
2 difference between groups at their longest follow-up (risk difference = 0.00, 95% CI -0.02 to 0.01,
3 p=0.38). There was no evidence of statistical heterogeneity across trials (P value=0.91, I²=0%).

4
5
6
7 (*figure 2*).

8 9 *Cardiovascular mortality*

10
11
12 Nine studies (n = 1,182 participants) reported cardiovascular mortality (*figure 3*). There was no
13 difference between groups at their longest follow-up (risk difference = -0.01, 95% CI -0.02 to 0.01,
14 p=0.25). There was no evidence of statistical heterogeneity across trials (P value=0.44, I²=0%).

15
16
17 (*figure 3*).

18 19 *Hospital admissions*

20
21
22
23 Eleven studies (n= 1,768 participants) reported on proportion with one or more hospital
24 admissions (*figure 4*). There was a reduction of borderline statistical significance (risk difference = -
25 0.05, 95% CI -0.10 to -0.00, p=0.05). There was evidence of statistical heterogeneity across trials (P
26 value=0.002, I²=64%).

27
28
29 (*figure 4*).

30 31 **Discussion**

32
33
34 The effectiveness of exercise-based CR in patients with coronary artery disease has been
35 determined by Cochrane systematic reviews and meta-analyses, providing clinicians and academics with
36 the highest level of evidence over the last 17 years(10, 52, 53). The latest Cochrane review, conducted in
37 2016, found benefits of exercise-based CR in terms of reduced cardiovascular mortality and hospital
38 admissions, but unlike previous Cochrane reviews, found no effect on all-cause mortality(10). We
39 identified that data from studies included in this review dated back as far as 1975(54). By including such
40 historical data, this Cochrane review may not be correctly assessing the potential effect of contemporary
41 exercise-based CR.

42
43
44 The current review aimed to assess the effect of exercise-based CR in the era of improved
45 reperfusion strategies and simultaneous advances in pharmacological management, by only including
46 studies whose participants were recruited after the year 2000. The majority of interventions tested in the
47 twenty-two included trials (*table 3*) delivered an intervention recognised as best practice in exercise-
48 based CR, where multiple approaches, including educational/psychosocial components, as well as the
49 exercise component were used(2, 3, 8).

50
51
52 The current analyses demonstrated no improvement in all-cause mortality from participation in
53 exercise-based CR: the risk difference was 0.00 (95% CI -0.02 to 0.01). The largest trial included in our
54 analysis, the UK-based Rehabilitation after myocardial infarction trial (RAMIT) trial, sought to show a
55
56
57

1 20% reduction in relative risk based on an 11% mortality; i.e. a 2.2% risk difference(24). The limits of the
2 95% confidence interval for the effect size in our analysis do not include the RAMIT trial's pre-specified
3 clinically important difference. We therefore conclude that it is extremely unlikely that there is a
4 worthwhile benefit from exercise-based CR on all-cause mortality. Furthermore, it is unlikely that future
5 trials of similar interventions and populations, will change this conclusion. This is supported by a recent
6 meta-analysis which included participants with other forms of atherosclerotic cardiovascular disease i.e.
7 peripheral artery disease, ischaemic cerebrovascular accidents, diabetes and hypertension. They too
8 found a zero effect on all-cause mortality (relative risk 1.00, 95% CI 0.88 to 1.14)(55). With the mean
9 follow-up period for all studies included in our review being 24.7 months, it may be that any benefits on
10 mortality will accrue over a longer follow-up. However, the absence of any kind of signal in this review
11 means a substantial longer-term benefit is unlikely.

12 The current analyses do not quite exclude a worthwhile benefit of exercise-based CR on hospital
13 admissions. Whilst a risk difference of -0.05 (95% CI -0.10 to -0.00) is of borderline statistical
14 significance, it is probably clinically unimportant in the context of no change in all-cause mortality.

15 From the studies included in this review, we do not know if there is a worthwhile benefit on
16 quality of life, as a meta-analysis was not conducted. However, the authors of the 2016 Cochrane review
17 reported that in four of the twenty-two studies included in this review, there was a significantly higher
18 quality of life in at least half or more of the sub-scales(32, 45, 46, 49).

19 Based on the present data, we are also unable to comment on whether exercise-based CR might
20 be cost-effective. Five of the studies in this review included a within trial health economic evaluation(30,
21 40, 43, 44, 50). Of these five papers, three studies showed no difference in healthcare costs between
22 groups(40, 43, 50), one found healthcare costs to be lower for exercise-based CR(30), and one failed to
23 report a p-value for cost difference(44). Whilst a decrease, of borderline statistical significance, in
24 hospital admissions may improve quality of life for patients, it is unclear if this confers any economic
25 benefit, in the absence of robust cost-effectiveness analyses.

26 It may be that exercise-based CR has an effect on other outcomes, not specifically addressed in
27 this review, such as cardiorespiratory fitness, lifestyle risk factor management, adherence to medication,
28 diet, smoking cessation, psychosocial health and return to work(7, 8, 56, 57). If the focus of future
29 research is on measuring and improving these outcomes, attention will be needed to develop the best
30 multi-component intervention.

31 ***Strengths and Limitations***

32 To our knowledge, this is the first systematic review of exercise-based CR that has pooled data
33 relevant to contemporary medical management of patients diagnosed with coronary artery disease.
34 Although we have not done a de novo quality assessment of 21/22 studies included in this review and
35 instead are relying on a previous Cochrane assessment, it is unlikely that we would have drawn different
36 conclusions from such an assessment(10).

37 The current review does not provide information on participant baseline characteristics. In the
38 majority of studies (20/22; 91%), however, baseline characteristics were comparable between the
39 intervention and control groups(10, 29).

1
2
3 Whilst there was no evidence of statistical heterogeneity across trials for all outcome measures
4 (P value<0.01, I²>30%), except for hospital admissions, there was substantial context and interventional
5 heterogeneity. The studies came from a wide range of clinical environments and countries, and the
6 interventions delivered ranged greatly in quality. When compared with both the BACPR 'minimum
7 standards and core components'(8) and ACPICR guidelines(6), there was considerable variation in the
8 exercise interventions delivered (*table 3*). Critics have questioned the exercise component reported in
9 the largest included study, the RAMIT trial (n=1813)(31). They argued that under-dosage of exercise
10 intensity and duration may have led to the inconclusive result(58). Several other studies included in this
11 review also fail to report on the intensity, modality and/or duration of the exercise intervention. Exercise
12 and physical activity has a 'dose-response' relationship with cardiovascular disease risk(59). Moreover, a
13 higher exercise capacity (VO₂ peak) is associated with an improvement in mortality risk(60, 61). If
14 patients engaging in exercise-based CR do not achieve the correct dose of exercise, a physiological
15 benefit is unlikely. It is a legitimate concern that participants in many included trials may not have
16 received an adequate dose of exercise. In the era of contemporary medical management, higher intensity
17 exercise protocols might be appropriate and effective(62).

18
19 One major concern is the reporting of adherence to, and fidelity of, exercise interventions(10).
20 Whilst the majority of studies included in this review report the intended prescription exercise dose
21 (*table 3*), it is not possible to determine adherence and fidelity. Without basic reporting of these
22 parameters, the actual exercise dose received cannot be quantified. This may have a significant bearing
23 on intervention efficacy and the results of this meta-analysis.
24
25
26
27
28

29 **Conclusion**

30
31
32 Based on the outcomes of all-cause mortality and cardiovascular mortality, our analysis
33 indicates conclusively that the current approach to exercise-based CR has no effect when compared to a
34 no exercise control. There may be a small reduction in hospital admissions following exercise-based CR
35 that is unlikely to be clinically important.
36

37 The continued delivery of exercise-based CR needs to be supported by new research to show its
38 impact on health-related quality of life and whether it is a cost-effective intervention.
39
40

41 **Contributors**

42
43
44 RP and MU were principally responsible for the study concept and design. RP and GM were
45 responsible for study selection, data extraction and risk of bias assessment. RP updated and ran the
46 searches. RP, MU and PK were responsible for statistical analysis and interpretation of data. GM and SE
47 provided clinical advice. RP and MU wrote the first draft of the review and all co-authors contributed to
48 review and editing of drafts of the report. All authors approved the final manuscript. RP is the study
49 guarantor and had full access to all trial level data in the review, takes responsibility for the integrity of
50 the data, and accuracy of the data analysis, and had final responsibility to submit for publication.
51
52
53

54 **Copyright**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all *authors*, a worldwide license to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) license any third party to do any or all of the above.

Funding

This review was not funded and hence no role was played by funders in the conception, data synthesis, analysis, interpretation or in the drafting of the manuscript.

Competing interests

All authors have completed the *Unified Competing Interest form* (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Ethical Approval

Ethical approval not required.

Data sharing

No additional data available.

The lead author (RP) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.

Tables

Table 1. Risk of bias assessment for additional study

| Santaularia <i>et al.</i> 2017 | | |
|--------------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Bias | Authors' judgement | Support for judgement |
| Random sequence | Low risk | A randomisation list in blocks of ten was created by a computer random number generator. The randomisation list and the allocation |

| | | | |
|----|------------------|-----------|-------------------------------------------------------------------------|
| 1 | generation | | of patients to each group were independently controlled by the Clinical |
| 2 | (selection bias) | | Trials Unit.' |
| 3 | | | |
| 4 | Allocation | | A randomisation list in blocks of ten was created by a computer |
| 5 | concealment | | random number generator. The randomisation list and the allocation |
| 6 | (selection bias) | Low risk | of patients to each group were independently controlled by the Clinical |
| 7 | | | Trials Unit.' |
| 8 | Blinding of | | |
| 9 | outcome | | An independent committee that was blind to the patients' treatment |
| 10 | assessment | | group assessed the main outcomes. This committee comprised a |
| 11 | (detection bias) | Low risk | cardiologist, a rehabilitation cardiologist and a health information |
| 12 | All outcomes | | manager, all from different centres.' |
| 13 | Incomplete | | |
| 14 | outcome data | | |
| 15 | (attrition bias) | Low risk | There was no loss to follow-up. |
| 16 | All outcomes | | |
| 17 | Selective | | All outcomes described in the methods were reported in the results. |
| 18 | reporting | Low risk | Results regarding quality of life are presented in supplementary data |
| 19 | (reporting bias) | | but were not required for the current review. |
| 20 | Groups | | |
| 21 | balanced at | Low risk | No significant differences between groups were observed, with the |
| 22 | baseline | | exception of gender: 23% of the control group were women compared |
| 23 | | | with 7% in the intervention group ($p=0.049$). |
| 24 | Intention-to- | | |
| 25 | treat analysis | High risk | No analysis was conducted. |
| 26 | conducted | | |
| 27 | Groups received | | |
| 28 | same treatment | Low risk | Patients assigned to the control group received standard care given at |
| 29 | (apart from the | | the hospital'. In addition to standard care, patients randomised to the |
| 30 | intervention) | | intervention group....' |

Table 2. Overview of participants, recruitment period, patient diagnosis and medical therapy

| Reference s, country | N | Mean age (year s) | Male participan ts (%) | Recruitme nt period (years) | Maximu m follow- up period | Patient diagnosis | Medication |
|---------------------------------------------------|-----|----------------------------|------------------------------|-----------------------------------|----------------------------------------|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aronov <i>et al.</i> (2010), Russia | 392 | 61.4 | 73.5 | None specified | 1 year | AMI, stable angina, unstable angina or myocardial revascularisation. | Standard medical therapy- β -blocker, acetylsalicyclic acid or other antithrombotic drug, nitrate, ACE inhibitor. Some patients on lipid- lowering drugs. |
| Belardinelli <i>et al.</i> (2001), Italy | 118 | 61 | 100 | None specified | 33 months | CAD including AMI. Successful PCI in 1 or 2 native epicardial coronary arteries only. | According to international accepted protocols- aspirin, ticlopidine, calcium antagonists, nitrates. |
| Briffa <i>et al.</i> (2005), Australia | 113 | 47.5 | 89.5 | None specified. | 1 year | Uncomplicated AMI or recovery from unstable angina. PCI, CABG, thrombolytic therapy. | Aspirin, antiarrhythmic agent, β -blocker, ACE inhibitor, calcium antagonist, long acting nitrate, diuretic. |

| | | | | | | | |
|----|-----------------------|-----|------|------|------------|------------------------|------------------------------------------|
| 1 | | | | | | 6 months | |
| 2 | Giallauria | | | | | AMI and undergone | |
| 3 | <i>et al.</i> | | | | None | primary or rescue | Aspirin, β -blocker, ACE |
| 4 | (2008), | 61 | 58.5 | 78.5 | specified. | PCI only. | inhibitor, ARB, statin. |
| 5 | Italy | | | | | | |
| 6 | | | | | | 1 year | |
| 7 | Hambrecht | | | | | Stable CAD defined | β -receptor antagonists, β - |
| 8 | <i>et al.</i> | | | | | by angina pectoralis | HMG-CoA reductase |
| 9 | (2004), | 101 | 56 | 87.3 | 1997-2001 | and amenable to PCI. | inhibitors, ACE inhibitor, |
| 10 | Germany | | | | | AMI patients | acetylsalicylic acid. |
| 11 | | | | | | 51 weeks | |
| 12 | Higgins <i>et al.</i> | | | | | Post-PCI patients | Reference to medical |
| 13 | (2001), | 105 | 60.8 | 81.3 | 1995-1997 | only. No AMI 1 | therapy, only breakdown |
| 14 | Australia | | | | | month pre- | for lipid lowering |
| 15 | | | | | | procedure. | medication. |
| 16 | | | | | | 12 months | |
| 17 | | | | | | Patients hospitalised | |
| 18 | Houle <i>et al.</i> | | | | | for an ACS (unstable | Reference to medication in |
| 19 | (2012), | 65 | 51.5 | 100 | 2007-2008 | angina, non-ST- | usual care group, but no |
| 20 | Canada | | | | | elevation or ST | breakdown. |
| 21 | | | | | | elevation MI). PCI, | |
| 22 | | | | | | CABG or no | |
| 23 | | | | | | revascularisation | |
| 24 | | | | | | procedure. | |
| 25 | | | | | | 6 months | |
| 26 | | | | | | AMI only. | |
| 27 | | | | | | Thrombolytic | Aspirin, β -blocker, ACE |
| 28 | | | | | | therapy, one patient | inhibitor, calcium channel |
| 29 | | | | | | in the exercise | blockers, nitrates, |
| 30 | | | | | | treatment group had | cholesterol-lowering |
| 31 | | | | | | primary angioplasty. | agents, |
| 32 | | | | | | 24 weeks | |
| 33 | | | | | | Diagnosis of IHD | |
| 34 | | | | | | (angina, MI, | |
| 35 | | | | | | revascularisation, | |
| 36 | | | | | | including | |
| 37 | | | | | | angioplasty, stent, or | |
| 38 | | | | | | CABG). | No description. |
| 39 | | | | | | 10 years | |
| 40 | | | | | | (None | Medication regimens |
| 41 | | | | | | specified) 2 | employed in secondary |
| 42 | | | | | | year | prevention at discharge |
| 43 | | | | | | enrollment | were clearly insufficient by |
| 44 | | | | | | period. | standard criteria but |
| 45 | | | | | | | currently meet Spanish |
| 46 | | | | | | | and European guidelines'. |
| 47 | | | | | | 6 months | |
| 48 | | | | | | Stable angina and | |
| 49 | | | | | | unstable angina, post | Aspirin, β -blocker, ACE |
| 50 | | | | | | PCI only. AMI | inhibitor, ARB, statin, |
| 51 | | | | | | patients excluded. | acetylsalicylic acid. |
| 52 | | | | | | 6 months | |
| 53 | | | | | | Undergone CABG | Participants received |
| 54 | | | | | | surgery. Unknown | advice that focused on |
| 55 | | | | | | whether AMI | medications', no |
| 56 | | | | | | patients included. | breakdown. |
| 57 | | | | | | 12 months | |
| 58 | | | | | | Recent coronary | |
| 59 | | | | | | event defined as | β -blocker, antithrombotics, |
| 60 | | | | | | AMI, PCI, CABG or | calcium antagonists, lipid- |
| | | | | | | without invasive | lowering agents, diuretics. |
| | | | | | | procedure. | |
| | | | | | | 12 months | |
| | | | | | | ACS including AMI, | Reference to a 'descriptive |
| | | | | | | underwent successful | summary in supplemental |
| | | | | | | PCI only. | table', no access. |
| | | | | | | 12 months | |
| | | | | | | AMI only, no | Reference to cardiac |
| | | | | | | evidence of | medication, but no |
| | | | | | | revascularisation | breakdown |

| | | | | | | | |
|----|-----------------------|-----|------|------|------------|-------------------|------------------------------------|
| 1 | Spain | | | | | | procedure. |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | | | | | NR | Reference to 'lipid- |
| 5 | Seki <i>et al.</i> | | | | | | lowering drugs and other |
| 6 | (2008), | 39 | 57.8 | 83.8 | None | | medications', no |
| 7 | Japan | | | | specified. | AMI, PCI or CABG. | breakdown. |
| 8 | | | | | | | |
| 9 | Toobert <i>et al.</i> | | | | | 24 | CAD defined as |
| 10 | (2000), | 25 | 64.5 | 0 | None | months | atherosclerosis, AMI, |
| 11 | USA | | | | specified. | | PCI or CABG. |
| 12 | | | | | | | Anti-hypertensive and |
| 13 | VHSG <i>et al.</i> | | | | | 2 years | hypolipidemic |
| 14 | (2003), | 197 | 64 | 75.8 | None | | medications. |
| 15 | Norway | | | | specified. | | Aspirin, β -blocker, statin, |
| 16 | | | | | | | ACE inhibitor, calcium |
| 17 | Wang <i>et al.</i> | | | | | 6 months | antagonist, warfarin. |
| 18 | (2012), | 160 | 67 | 63.5 | 2005-2007 | | Anti-platelet, Nitrate, β - |
| 19 | China | | | | | | blocker, ACE inhibitor, |
| 20 | | | | | | | calcium antagonist, statin. |
| 21 | | | | | | 7 to 9 | Aspirin, β -blocker, ACE |
| 22 | West <i>et al.</i> | 181 | | | | years | inhibitor, diuretic, long |
| 23 | (2012), UK | 3 | 51.9 | 93.9 | 1997-2000 | | acting nitrate/ calcium |
| 24 | | | | | | | channel blocker, statin, |
| 25 | | | | | | | GTN. |
| 26 | | | | | | | |
| 27 | | | | | | 2 years | Anti-platelet, β -blocker, |
| 28 | Yu <i>et al.</i> | | | | | | calcium channel blocker, |
| 29 | (2004), | 269 | 56 | 83.9 | None | | nitrate, statin, ACE |
| 30 | China | | | | specified. | | inhibitor, diuretic. |
| 31 | | | | | | 1 year | Antithrombotics, lipid- |
| 32 | Zwisler <i>et al.</i> | | | | | | lowering drugs, β -blocker, |
| 33 | (2008), | 446 | 55.5 | 72.1 | 2000-2003 | | calcium antagonists, ACE |
| 34 | Denmark | | | | | | inhibitor, diuretic, long- |
| 35 | | | | | | | acting nitrates. |

AMI- Acute Myocardial Infarction, CAD- Coronary Artery Disease, PCI- Percutaneous Coronary Intervention, IHD- Ischaemic Heart Disease, CABG- Coronary Artery Bypass Graft, CHD- Coronary Heart Disease, ACS- Acute Coronary Syndrome, ACE- Angiotensin-Converting-Enzyme, ARB- Angiotensin Receptor Blockers, GTN- Glyceryl Trinitrate.

Table 3. Overview of exercise interventions

| Reference s, country | Exercise Intervention | Study Duration | | | | Additional |
|------------------------------------------------|-----------------------------------------------------------------|------------------------------|--------------|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------|------------|
| | | Exercise | Modality | Duration | Session Duration/Frequency/Intensity | |
| Aronov <i>et al.</i> (2010), Russia | Moderate intensity physical training (unknown setting). | Cycle ergometer. | 12 months | 45 minutes- 60 minutes/ 3 sessions per week/ 50-60% of the performed capacity by bicycle ergometry. | None specified. | |
| Belardinelli <i>et al.</i> (2001), Italy | Moderate intensity exercise (supervised in hospital gym). | Cycle ergometer. | 6 months | 53 minutes/ 3 sessions per week/ 60% of peak oxygen uptake (VO ₂ Peak). | None specified. | |
| Briffa <i>et al.</i> (2005), Australia | Aerobic circuit training (supervised in hospital). | Aerobic circuit training. | 6 weeks | 60-90 minutes/ 3 sessions per week/ not specified. | Education and psychosocial counselling. | |
| Giallauria <i>et al.</i> (2008), Italy | Moderate intensity exercise (supervised in centre). | Cycle ergometer. | 6 months | 40 minutes/ 3 sessions per week/ 60%-70% of peak oxygen uptake (VO ₂ Peak). | None specified. | |
| Hambrecht <i>et al.</i> | Moderate intensity exercise (supervised in | Cycle ergometer. | 12 months | 10 minutes- 42 sessions per week (hospital), 20 minutes- 7 sessions per | None specified. | |

| | | | | | | |
|----|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 1 | (2004), Germany | hospital & unsupervised at home). | | | week (home) plus 60 minutes' group training- 1 session per week/ 70% of symptom-limited max HR. | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | Higgins <i>et al.</i> (2001), Australia | Moderate intensity walking programme (unsupervised at home). | Walking. | Not specified. | Not specified/ not specified/ not specified. | Psychologica l plus education. |
| 6 | | | | | | |
| 7 | | | | | | |
| 8 | | | | | | |
| 9 | Houle <i>et al.</i> (2012), Canada | Pedometer-based walking programme (unsupervised at home). | Walking. | 12 months | Not specified/ not specified/ not specified. | Education plus socio- cognitive. |
| 10 | | | | | | |
| 11 | | | | | | |
| 12 | | | | | | |
| 13 | Kovoor <i>et al.</i> (2006), Australia | Standard Cardiac Rehabilitation programme (unknown setting). | Not specified. | 5 weeks | Not specified/ 2-4 sessions per week/ not specified. | Education and counselling |
| 14 | | | | | | |
| 15 | | | | | | |
| 16 | | | | | | |
| 17 | Maddison <i>et al.</i> (2014), New Zealand | Automated package of text messages to increase exercise behaviour (unsupervised at home). | Moderate to vigourous aerobic exercise e.g. walking and household chores. | 24 weeks | Minimum of 30 minutes/ at least 5 sessions per week/ not specified. | Optional access to other cardiac rehabilitatio n service or support. |
| 18 | | | | | | |
| 19 | | | | | | |
| 20 | | | | | | |
| 21 | | | | | | |
| 22 | | | | | | |
| 23 | Maroto <i>et al.</i> (2005), Spain | Individualised physical training (supervised in hospital gym). | Physiotherapy and aerobic training on mats or a cycle ergometer. | 3 months | 60 minutes/ 3 sessions per week/ 75- 85% max HR. | Psychologica l, education plus return to work counselling. |
| 24 | | | | | | |
| 25 | | | | | | |
| 26 | | | | | | |
| 27 | | | | | | |
| 28 | Munk <i>et al.</i> (2009), Norway | Moderate/high intensity interval training (supervised in centre). | Cycle ergometer or running. | 6 months | 60 minutes/ 3 sessions per week/ 60- 70% & 80-90% max HR. | Spine & abdominal resistance training. |
| 29 | | | | | | |
| 30 | | | | | | |
| 31 | Mutwalli <i>et al.</i> (2012), Saudi Arabia | Moderate intensity walking programme (unsupervised at home). | Walking. | 6 months | 30 minutes/ 7 sessions per week/ not specified. | Education. |
| 32 | | | | | | |
| 33 | | | | | | |
| 34 | | | | | | |
| 35 | | | | | | |
| 36 | Oerkild <i>et al.</i> (2012), Denmark | Moderate intensity exercise (unsupervised at home). | Individualised | 12 months | 30 minutes/ 6 sessions per week/ 11- 13 on the Borg Scale. | Risk factor management . |
| 37 | | | | | | |
| 38 | | | | | | |
| 39 | Reid <i>et al.</i> (2012), Canada | Internet based physical activity plan and motivational tool to increase physical activity (unsupervised at home). | Not specified. | 20 weeks | Not specified/ not specified/ not specified. | None specified. |
| 40 | | | | | | |
| 41 | | | | | | |
| 42 | | | | | | |
| 43 | | | | | | |
| 44 | | | | | | |
| 45 | | | | | | |
| 46 | Santaularia <i>et al.</i> (2017), Spain | Outpatient exercise training programme (supervised in hospital). | Cycle ergometer | 10 weeks | 60 minutes/ 3 sessions per week/ 75- 90% max HR (RPE 11-15 on Borg Scale) | Resistance training, education and risk factor management . |
| 47 | | | | | | |
| 48 | | | | | | |
| 49 | | | | | | |
| 50 | | | | | | |
| 51 | Seki <i>et al.</i> (2008), Japan | Moderate intensity aerobic exercise (supervised in centre & unsupervised at home). | Walking, cycle ergometer, jogging. | 6 months | 50-110 minutes- 1 session per week (centre), ≥ 30 minutes- 2 sessions per week (home)/ 12-13 on the standard Borg scale. | Education. |
| 52 | | | | | | |
| 53 | | | | | | |
| 54 | | | | | | |
| 55 | Toobert <i>et al.</i> (2000), USA | Walking or aerobics (supervised in centre & unsupervised at home). | Walking or aerobics. | 24 months | 60 minutes- 7 sessions per week (centre), 60 minutes- 3 sessions per week (home)/ Individually prescribed. | Education and psychologica l support. |
| 56 | | | | | | |
| 57 | | | | | | |
| 58 | | | | | | |
| 59 | | | | | | |
| 60 | | | | | | |

| | | | | | | |
|----|--------------------|-------------------------|------------------|------------|----------------------------------------|--------------|
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | VHSG <i>et al.</i> | Dynamic endurance | Dynamic | | | Education |
| 4 | (2003), | physical activity | endurance | | 55 minutes/ 2 sessions per week/ | and |
| 5 | Norway | (supervised, group | training. | 15 weeks | RPE 11-13 on the Borg Scale, | psychologica |
| 6 | | sessions in centre). | | | increased to 13-15 after 6 weeks. | l support. |
| 7 | Wang <i>et al.</i> | | | | | |
| 8 | (2012), | Not specified. | Not specified. | Not | Not specified/ not specified/ not | Education. |
| 9 | China | | | specified. | specified. | |
| 10 | | | Varied by centre | | | |
| 11 | | | (exercise | | | Education |
| 12 | West <i>et al.</i> | Not specified, multi- | equipment in | | | plus |
| 13 | (2012), UK | centre (supervised in | physiotherapy | 6-8 | Averaged 20 hours over 6-8 weeks/ 1- | psychologica |
| 14 | | centre). | gyms). | weeks | 2 sessions per week/ not specified. | l support. |
| 15 | | | Walking, | | | |
| 16 | | Ambulatory and | treadmill, cycle | | | |
| 17 | Yu <i>et al.</i> | aerobic cardiovascular | ergometry, | | 2 hours/ 2 sessions per week (centre), | Resistance |
| 18 | (2004), | training (supervised in | rowing, stepper, | | not specified (home)/ 65-85% of | training and |
| 19 | China | hospital and centre, | arm ergometry, | 8 1/2 | maximal aerobic capacity (VO2 | education. |
| 20 | | unsupervised at home). | dumbbell. | months | Peak). | |
| 21 | Zwisler <i>et</i> | Intensive CR | | | | Education |
| 22 | <i>al.</i> (2008), | programme | | | Not specified/ 2 sessions per week/ | and |
| 23 | Denmark | (supervised in centre). | Not specified. | 6 weeks | not specified. | psychosocial |
| 24 | | | | | | support. |

HR- Heart Rate, VO₂ Peak- Peak Oxygen Uptake

References

1. World Health Organisation. Top 10 causes of death worldwide- Fact Sheet 2017 29/05/2017. Available from: <http://www.who.int/mediacentre/factsheets/fs310/en/>.
2. NICE. Myocardial Infarction: cardiac rehabilitation and prevention of further cardiovascular disease 2013 31/05/2017. Available from: <https://www.nice.org.uk/guidance/cg172/resources/myocardial-infarction-cardiac-rehabilitation-and-prevention-of-further-cardiovascular-disease-pdf-35109748874437>.
3. BACPR. Cardiovascular Disease Prevention and Rehabilitation 2012 31/05/2017. Available from: http://www.bacpr.com/resources/46C_BACPR_Standards_and_Core_Components_2012.pdf.
4. Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. *Eur J Prev Cardiol.* 2014;21(6):664-81.
5. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. *J Cardiopulm Rehabil Prev.* 2007;27(3):121-9.
6. ACPICR. Standards for Physical Activity and Exercise in the Cardiovascular Population 2015 31/05/2017. Available from: http://acpicr.com/sites/default/files/ACPICR_Standards_2015.pdf.
7. Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. *BMJ.* 2015;351:h5000.
8. Buckley JP, Furze G, Doherty P, Speck L, Connolly S, Hinton S, et al. BACPR scientific statement: British standards and core components for cardiovascular disease prevention and rehabilitation. *Heart.* 2013;99(15):1069-71.
9. Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. *BMJ.* 2010;340:b5631.

10. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. *J Am Coll Cardiol*. 2016;67(1):1-12.
11. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet*. 2003;361(9351):13-20.
12. D'Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary angioplasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis. *Eur Heart J*. 2011;32(8):972-82.
13. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J*. 2003;24(1):28-66.
14. West RM, Cattle BA, Bouyssié M, Squire I, de Belder M, Fox KA, et al. Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. *Eur Heart J*. 2011;32(6):706-11.
15. Anon. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Multicentre international study: supplementary report. *Br Med J*. 1977;2(6084):419-21.
16. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. *Br Med J*. 1974;1(5905):436-40.
17. Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344(8934):1383-9.
18. Anon. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. *Circulation*. 1998;97(22):2202-12.
19. Skinner JS, Minhas R. Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction. *Heart*. 2007;93(7):864-6.
20. Eisen A, Bhatt DL. Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. *Heart*. 2016.
21. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. *Curr Probl Cardiol*. 2010;35(2):72-115.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *Open Med*. 2009;3(3):e123-30.
23. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J*. 1996;17(1):43-63.
24. Wood DA DP, Poutler N, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. *Heart*. 1998;80 Suppl 2:S1-29.
25. RevMan. The Nordic Cochrane Centre: The Cochrane Collaboration, version 5.3 (Review Manager)2014.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-60.
27. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
28. Kadda O, Kotanidou A, Manginas A, Stavridis G, Nanas S, Panagiotakos DB. Lifestyle intervention and one-year prognosis of patients following open heart surgery: a randomised clinical trial. *Journal of Clinical Nursing*. 2015;24(11-12):1611-21.
29. Santaularia N, Caminal J, Arnau A, Perramon M, Montesinos J, Abenoza Guardiola M, et al. The efficacy of a supervised exercise training programme on readmission rates in patients with myocardial ischemia: Results from a randomised controlled trial. *European Journal of Cardiovascular Nursing*. 2017;16(3):201-12.
30. Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation*. 2004;109(11):1371-8.
31. West RR, Jones DA, Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. *Heart*. 2012;98(8):637-44.
32. Belardinelli R, Paolini I, Cianci G, Piva R, Georgiou D, Purcaro A. Exercise training intervention after coronary angioplasty: the ETICA trial. *J Am Coll Cardiol*. 2001;37(7):1891-900.
33. Giallauria F, Cirillo P, Lucci R, Pacileo M, De Lorenzo A, D'Agostino M, et al. Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. *Eur J Cardiovasc Prev Rehabil*. 2008;15(1):113-8.

34. Maroto JM, Artigao Ramírez R, Morales Durán MD, de Pablo Zarzosa C, Abraira V. [Cardiac rehabilitation in patients with myocardial infarction: a 10-year follow-up study]. *Rev Esp Cardiol*. 2005;58(10):1181-7.
35. Munk PS, Staal EM, Butt N, Isaksen K, Larsen AI. High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation A randomized controlled trial evaluating the relationship to endothelial function and inflammation. *Am Heart J*. 2009;158(5):734-41.
36. Oerkild B, Frederiksen M, Hansen JF, Prescott E. Home-based cardiac rehabilitation is an attractive alternative to no cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial. *BMJ Open*. 2012;2(6).
37. Vestfold Heartcare Study Group. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. *Eur J Cardiovasc Prev Rehabil*. 2003;10(6):429-37.
38. Zwisler AD, Soja AM, Rasmussen S, Frederiksen M, Abedini S, Abadini S, et al. Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial. *Am Heart J*. 2008;155(6):1106-13.
39. Aronov DM, Krasnitskii VB, Bubnova MG, Pozdnyakov IM, Ioseliani DG, Shchegol'kov AN, et al. [Physical training at ambulatory-polyclinical stage in complex rehabilitation and secondary prevention of patients with ischemic heart disease after acute incidents. Effect on physical working capacity, hemodynamics, blood lipids, clinical course and prognosis (Russian cooperative study)]. *Kardiologiya*. 2009;49(3):49-56.
40. Briffa TG, Eckermann SD, Griffiths AD, Harris PJ, Heath MR, Freedman SB, et al. Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. *Med J Aust*. 2005;183(9):450-5.
41. Higgins HC, Hayes RL, McKenna KT. Rehabilitation outcomes following percutaneous coronary interventions (PCI). *Patient Educ Couns*. 2001;43(3):219-30.
42. Houle J, Doyon O, Vadeboncoeur N, Turbide G, Diaz A, Poirier P. Effectiveness of a pedometer-based program using a socio-cognitive intervention on physical activity and quality of life in a setting of cardiac rehabilitation. *Can J Cardiol*. 2012;28(1):27-32.
43. Kovoov P, Lee AK, Carrozzi F, Wiseman V, Byth K, Zecchin R, et al. Return to full normal activities including work at two weeks after acute myocardial infarction. *Am J Cardiol*. 2006;97(7):952-8.
44. Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr A, Jiang Y, et al. A mobile phone intervention increases physical activity in people with cardiovascular disease: Results from the HEART randomized controlled trial. *Eur J Prev Cardiol*. 2014;22(6):701-9.
45. Mutwalli HA, Fallows SJ, Arnous AA, Zamzami MS. Randomized controlled evaluation shows the effectiveness of a home-based cardiac rehabilitation program. *Saudi Med J*. 2012;33(2):152-9.
46. Reid RD, Morrin LI, Beaton LJ, Papadakis S, Kocourek J, McDonnell L, et al. Randomized trial of an internet-based computer-tailored expert system for physical activity in patients with heart disease. *Eur J Prev Cardiol*. 2012;19(6):1357-64.
47. Seki E, Watanabe Y, Shimada K, Sunayama S, Onishi T, Kawakami K, et al. Effects of a phase III cardiac rehabilitation program on physical status and lipid profiles in elderly patients with coronary artery disease: Juntendo Cardiac Rehabilitation Program (J-CARP). *Circ J*. 2008;72(8):1230-4.
48. Toobert DJ, Glasgow RE, Radcliffe JL. Physiologic and related behavioral outcomes from the Women's Lifestyle Heart Trial. *Ann Behav Med*. 2000;22(1):1-9.
49. Wang W, Chair SY, Thompson DR, Twinn SF. Effects of home-based rehabilitation on health-related quality of life and psychological status in Chinese patients recovering from acute myocardial infarction. *Heart Lung*. 2012;41(1):15-25.
50. Yu CM, Lau CP, Chau J, McGhee S, Kong SL, Cheung BM, et al. A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention. *Arch Phys Med Rehabil*. 2004;85(12):1915-22.
51. Toobert DJ, Strycker LA, Glasgow RE. Lifestyle change in women with coronary heart disease: what do we know? *J Womens Health*. 1998;7(6):685-99.
52. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. *Cochrane Database Syst Rev*. 2001(1):CD001800.
53. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev*. 2011(7):CD001800.
54. Wilhelmsen L, Sanne H, Elmfeldt D, Grimby G, Tibblin G, Wedel H. A controlled trial of physical training after myocardial infarction. Effects on risk factors, nonfatal reinfarction, and death. *Prev Med*. 1975;4(4):491-508.
55. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. *Int J Cardiol*. 2017;232:294-303.
56. Valkeinen H, Aaltonen S, Kujala UM. Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis. *Scand J Med Sci Sports*. 2010;20(4):545-55.

- 1 57. Yohannes AM, Doherty P, Bundy C, Yalfani A. The long-term benefits of cardiac rehabilitation on
2 depression, anxiety, physical activity and quality of life. *J Clin Nurs*. 2010;19(19-20):2806-13.
- 3 58. Conraads VM, Denollet J, De Maeyer C, Van Craenenbroeck E, Verheyen J, Beckers P. Exercise training
4 as an essential component of cardiac rehabilitation. *Heart*. 2012;98(8):674-5; author reply 5.
- 5 59. Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity
6 and risk of coronary heart disease: a meta-analysis. *Circulation*. 2011;124(7):789-95.
- 7 60. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a
8 quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis.
9 *JAMA*. 2009;301(19):2024-35.
- 10 61. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of
11 Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory,
12 musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci
13 Sports Exerc*. 2011;43(7):1334-59.
- 14 62. McGregor G, Nichols S, Hamborg T, Bryning L, Tudor-Edwards R, Markland D, et al. High-intensity
15 interval training versus moderate-intensity steady-state training in UK cardiac rehabilitation programmes (HIIT or
16 MISS UK): study protocol for a multicentre randomised controlled trial and economic evaluation. *BMJ Open*.
17 2016;6(11):e012843.

18 **Legends**


19 *Figure 1.* Summary of study selection process

20 *Figure 2.* All-cause mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual
21 studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95%
22 confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR-
23 Cardiac Rehabilitation.

24 *Figure 3.* Cardiovascular mortality for studies at their longest follow-up period. Filled squares represent the risk difference for
25 individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent
26 their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects
27 analysis. CR- Cardiac Rehabilitation.

28 *Figure 4.* Hospital admissions for studies at their longest follow-up period. Filled squares represent the risk difference for
29 individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent
30 their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects
31 analysis. CR- Cardiac Rehabilitation.

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 2. All-cause mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)




Figure 3. Cardiovascular mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)




Figure 4. Hospital admissions for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)

Appendix 1

Search Name: CENTRAL repeat search- limited 2014-2017

Last Saved: 28/02/2017 14:50:03.214

Description: 28/02/17

ID Search

#1 MeSH descriptor: [Myocardial Ischemia] explode all trees

#2 (myocard* near isch*mi*):ti,ab,kw

#3 isch*mi* near heart:ti,ab,kw

#4 MeSH descriptor: [Coronary Artery Bypass] explode all trees

#5 myocard* near infarct*:ti,ab,kw

#6 heart near infarct*:ti,ab,kw

#7 angina:ti,ab,kw

#8 coronary near (disease* or bypass or thrombo* or angioplast*):ti,ab,kw

#9 MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees

#10 (percutaneous next coronary near/2 (interven* or revascular*))

#11 MeSH descriptor: [Angioplasty] explode all trees

#12 angioplast*

#13 ((coronary or arterial) near/4 dilat*)

#14 endoluminal next repair*



PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 2 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4,5 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4/appendix 1 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4,5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 4,5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 6 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis. | 6 |



PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 5,6 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 7 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 12-17 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 6, 12,13 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 8,9 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 8,9/figures 2,3,4 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 8,9 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 9,10 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 10,11 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 11 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 12 |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

BMJ Open

Is exercise-based cardiac rehabilitation effective: a systematic review and meta-analysis to re-examine the evidence.

| | |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-019656.R2 |
| Article Type: | Research |
| Date Submitted by the Author: | 26-Jan-2018 |
| Complete List of Authors: | Powell, Richard; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; University of Warwick, Warwick Clinical Trials Unit, Warwick Medical School, McGregor, Gordon; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; Coventry University, Faculty of Health and Life Sciences, Ennis, Stuart; University Hospitals Coventry and Warwickshire NHS Trust, Department of Cardiac Rehabilitation, Centre for Exercise & Health, ; Cardiff Metropolitan University, Cardiff Centre for Exercise & Health, Kimani, Peter; University of Warwick, Statistics and Epidemiology Unit, Warwick Medical School, Underwood, Martin; Warwick University, Warwick Clinical Trials Unit, Warwick Medical School, |
| Primary Subject Heading: | Rehabilitation medicine |
| Secondary Subject Heading: | Cardiovascular medicine, Evidence based practice |
| Keywords: | Coronary heart disease < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY, Myocardial infarction < CARDIOLOGY, REHABILITATION MEDICINE |
| | |

SCHOLARONE™
Manuscripts

Is exercise-based cardiac rehabilitation effective: a systematic review and meta-analysis to re- examine the evidence.

R Powell ^{1,5*}, G McGregor ^{1,2}, S Ennis ^{1,3}, P K Kimani ⁴, M Underwood ⁵

¹ Department of Cardiac Rehabilitation, Centre for Exercise & Health, University Hospital, Coventry, CV1 3LN, UK, ² Faculty of Health and Life Sciences, Coventry University, Coventry, CV1 5FB, UK, ³ Cardiff Centre for Exercise & Health, Cardiff Metropolitan University, Cardiff, CF5 2YB, UK ⁴ Statistics and Epidemiology Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK, ⁵ Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.

R Powell, Clinical Exercise Physiologist

G McGregor, Clinical Research Fellow

S Ennis, Clinical Exercise Physiologist

P K Kimani, Assistant Professor in Medical Statistics

M Underwood, Professor

*Correspondence to: Richard Powell, Richard.powell@uhcw.nhs.uk

Word count

3778 words

Abstract

Objectives

To determine the contemporary effectiveness of exercise-based Cardiac Rehabilitation (CR) in terms of all-cause mortality, cardiovascular mortality and hospital admissions.

Data sources

Studies included in, or meeting the entry criteria for the 2016 Cochrane review of exercise-based CR in patients with coronary artery disease.

Study eligibility criteria

Randomised controlled trials (RCTs) of exercise-based CR vs. a no exercise control whose participants were recruited after the year 2000.

Study appraisal and synthesis methods

Two separate reviewers independently screened the characteristics of studies. One reviewer quality appraised any new studies and assessed their risk of bias using the Cochrane Collaboration's recommended risk of bias tool. Data were reported as the risk difference (95% CI).

Results

We included 22 studies with 4,834 participants (mean age 59.5 years, 78.4% male). We found no differences in outcomes between exercise-based CR and a no exercise control at their longest follow-up period for: all-cause mortality (19 studies; n=4,194; risk difference 0.00, 95% CI -0.02 to 0.01, p=0.38) or cardiovascular mortality (9 studies; n = 1,182; risk difference -0.01, 95% CI -0.02 to 0.01, p=0.25). We found a small reduction in hospital admissions of borderline statistical significance (11 studies; n= 1,768; risk difference -0.05, 95% CI -0.10 to -0.00, p=0.05).

Conclusions and implications of key findings

Our analysis indicates conclusively that the current approach to exercise-based CR has no effect on all-cause mortality or cardiovascular mortality, when compared to a no exercise control. There may be a small reduction in hospital admissions following exercise-based CR that is unlikely to be clinically important.

Systematic review registration number

Prospero: International prospective register of systematic reviews. 2017. 42017073616.
Available from: https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017073616

Strengths and Limitations of this study

- To our knowledge, this is the first systematic review of exercise-based CR that has pooled data relevant to the current medical management of patients diagnosed with coronary artery disease.
- For analysis, we present the data as the risk difference (95% CI), which ensures all studies reporting data on the outcomes of interest were included.
- This systematic review pools data from studies that deliver an intervention recognised as best practice in exercise-based CR, where multiple approaches, including educational/psychosocial components, as well as the exercise component were used.
- We have not done a de novo quality assessment of 21/22 studies included in this review and instead rely on a previous Cochrane assessment.
- We did not include health-related quality of life as an outcome measure as this is unsuitable for meta-analysis.

Keywords

Coronary artery disease, exercise-based cardiac rehabilitation, all-cause mortality, cardiovascular mortality, hospital admissions.

Background

Cardiovascular disease is the world's biggest killer, accounting for 15 million deaths in 2015(1).

Secondary prevention of coronary artery disease through exercise-based CR in those who have a diagnosis of coronary artery disease, has the potential to reduce mortality, reduce hospital admissions and increase quality of life. Guidelines internationally endorse the use of exercise-based CR programmes(2-5).

Typically, exercise-based CR aims to achieve 20-60 minutes of moderate intensity continuous exercise, 3-5 times a week, with muscular strength and endurance exercises prescribed in conjunction(6). Additionally, most programmes include supplementary education (coronary risk factors and cardiac misconceptions), advice on diet and access to psychological support(2, 4, 7, 8). Typically exercise-based CR is delivered in a supervised centre-based setting, although home-based programmes are used(9).

A 2016 Cochrane review (63 studies, n=14,486 participants) found benefits of exercise-based CR for patients with coronary artery disease. Both cardiovascular mortality (27 studies, RR 0.74, 95% CI

1 0.64 to 0.86) and hospital re-admissions were reduced (15 studies, RR 0.82, 95% CI 0.70 to 0.96), when
2 compared to a no exercise control. However, in contrast to previous systematic reviews and meta-
3 analyses, there was no significant reduction in risk of re-infarction (36 studies, RR 0.90, 95% CI 0.79 to
4 1.04) or all-cause mortality (47 studies, RR 0.96, 95% CI 0.88 to 1.04)(10).
5
6

7 Over recent decades, the medical management of coronary artery disease has been transformed.
8 The introduction of primary percutaneous coronary intervention has reduced short-term major adverse
9 cardiac events and increased long-term survival(11-14). Simultaneously, there have also been widespread
10 advances in secondary preventative medical therapy. This includes the introduction of aspirin and beta-
11 blockers in the 1980s(15, 16), lipid-lowering statins and angiotensin converting enzyme inhibitors in the
12 1990s(17, 18) and more recently, the introduction of clopidogrel, a secondary anti-platelet, in 2007(19,
13 20). Age-adjusted mortality has decreased substantially in this population(21). Systematic reviews and
14 meta-analyses that include data from older studies may not correctly assess the potential effect of
15 exercise-based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
16 based CR. We hypothesise that previous reviews have overestimated the benefit of exercise-
17 based CR.
18
19
20
21

22 **Objectives**

23
24
25 To determine the contemporary effectiveness of exercise-based CR on all-cause mortality,
26 cardiovascular mortality, and hospital readmissions in patients with coronary artery disease.
27
28

29 **Methods**

30
31
32 We conducted and reported this meta-analysis in accordance with PRISMA (Preferred Reporting
33 Items for Systematic Reviews and Meta-Analyses)(22).
34
35

36 **Search Strategy**

37
38
39 To identify relevant studies, we started with the latest Cochrane review of exercise-based CR in
40 patients with coronary artery disease(10). Studies identified as 'awaiting assessment' or 'on-going' in this
41 review were re-visited to establish whether publication had been reached. To identify any new studies
42 published since the completion of the Cochrane review, an updated search was run on the 28/2/2017.
43 This search used the same search strategies as the latest Cochrane review(10). We searched Cochrane
44 Central Register of Controlled Trials (CENTRAL) (*appendix 1*), MEDLINE (Ovid), EMBASE (Ovid) and
45 CINAHL (EBSCO) databases. This approach allowed us to efficiently identify all relevant studies. Where
46 appropriate, we contacted original authors for clarification of any new included studies.
47
48

49 Two separate reviewers (RP and GM) independently screened the characteristics of studies in
50 the latest Cochrane review, studies identified as 'awaiting assessment' or 'on-going' and studies
51 identified in the updated search. Full text publications were retrieved to allow for further examination
52 and to verify study inclusion. Any discrepancies were resolved by a third reviewer (MU).
53
54
55
56
57
58
59
60

Criteria for considering studies

In 1996, The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology first recommended early (within two hours) primary percutaneous interventions in preference to thrombolytic therapy for acute myocardial infarction(23). Two years later, guidelines set by the Joint British recommendations on prevention of Coronary Heart Disease in Clinical Practice were published outlining the recommendations for best practice for secondary prevention medical therapies(24). Although there have been some changes, notably the introduction of a second anti-platelet agent in the early 2000s(19, 20), the approach to secondary prevention medical therapies has not changed since then. Allowing time for implementation of these guidelines and recommendations, we identified and included studies whose participants were recruited after the year 2000, to represent a contemporary population engaging in exercise-based CR.

Where there was no indication of recruitment period, the diagnosis and the secondary preventative medical therapy received by participants included in the trial determined the inclusion or exclusion of the study in the analysis.

Types of studies

We included randomised controlled trials of exercise-based CR compared to a no exercise control with a minimum follow-up period of six months. Data reported at the longest follow-up period were included in the analysis.

Types of participants

We used the same entry criterion as previous Cochrane reviews.

- People who have had a myocardial infarction, or who had undergone revascularisation (coronary artery bypass grafting or percutaneous coronary intervention) or who have angina pectoris or coronary artery disease defined by angiography.
- On optimal secondary preventative medical therapy defined by the Joint British recommendations on prevention of Coronary Heart Disease in Clinical Practice(24).
- Recruited to hospital-based, community-based or home-based CR programmes.

Types of intervention(s)

Randomised controlled trials consisted of supervised or non-supervised exercise-based CR. The intervention was exercise alone or exercise as part of a comprehensive CR programme (consisting of educational/psychosocial components). 'No exercise control' consisted of standard medical care,

1 including optimal secondary preventative medical therapy, education and advice about diet and exercise,
2 psychosocial support but with no formal exercise intervention.
3
4

5 ***Types of outcome measures***

6
7
8 We extracted data on: all-cause mortality, cardiovascular mortality and hospital re-admissions.
9 We did not include health-related quality of life as the authors of the 2016 Cochrane review found this
10 unsuitable for meta-analysis.
11
12

13 ***Data collection, statistical analysis and quality assessment***

14
15
16 We pooled data using Review Manager 5.3(25). Previous Cochrane reviews have presented the
17 data as individual and pooled risk ratio (95% CI). Using risk ratios automatically removed studies with
18 no events in either study arm from the analysis. Nine studies (n= 936 participants) reporting on all-
19 cause mortality, cardiovascular mortality or hospital re-admissions, were excluded from one or more
20 meta-analyses in the 2016 Cochrane review for this reason. We therefore present the data as the risk
21 difference (95% CI), which ensures all studies reporting data on the outcomes of interest were included.
22
23

24 We applied a random-effects model to all analyses given the clinical heterogeneity of individual
25 studies. Heterogeneity of included studies were tested statistically using the χ^2 test of heterogeneity and
26 I^2 statistic(26).
27

28 We did not repeat quality assurance checks already completed by the authors of the Cochrane
29 review. For separate study risk of bias breakdown for these studies, we refer the reader to the existing
30 *characteristics of studies*(10). For studies identified as 'awaiting assessment' or 'on-going' in the latest
31 Cochrane review, or in the updated search, we quality appraised these studies and assessed their risk of
32 bias using the Cochrane Collaboration's recommended risk of bias tool(27).
33
34
35

36 ***Assessment of risk of bias in additional included study***

37
38
39 One reviewer (RP) assessed the risk of bias in any additional included studies (*table 1*).
40 Assessment of three further quality domains as outlined in the latest Cochrane review was also
41 conducted (Groups balanced at baseline, Intention-to-treat analysis, Groups received comparable
42 treatment (except exercise)). A breakdown of the criteria used for assessing these three domains can be
43 found in the latest Cochrane review. Risk of bias assessments were checked by a second reviewer (GM)
44 and any discrepancies were resolved by a third reviewer (MU).
45
46
47

48 ***Patient Involvement***

49
50
51 No patients were involved in setting the objectives or outcome measures of this review, nor were
52 they involved in the design or implementation. No patients were involved in the analysis or
53 interpretation of the results, nor the writing of any drafts. There are no plans to disseminate the results
54 of the review to participants included in the studies of the review or any relevant patient networks.
55
56
57

Results

Studies retrieved

Of the sixty-three studies included in the Cochrane review, twenty-one studies met our entry criteria. We identified two additional relevant papers not included in the 2016 Cochrane review(28, 29). One was excluded because data for our specific research question were not available in a useable format(28). In total, twenty-two studies (n=4,834 participants) contributed to the analysis (*figure 1*). For the study identified from the updated search(29), there was a low risk of bias in all eight domains, apart from the intention-to-treat analysis, where there was no evidence of this analysis being conducted (*table 1*).

Three studies (3/22; 14%) reported on all three outcomes of interest, eleven studies (11/22; 50%) reported on two outcomes of interest and eight studies (8/22; 36%) reported on one outcome of interest.

Two studies for all-cause mortality(30, 31) and one study for cardiovascular mortality(30) reported data at varying follow-up periods (6 to 12 months; >12 to 36 months; >3 years). Data from these studies were taken at their longest follow-up period. Mean maximum follow-up period was 24.7 months. Maximum follow-up period ranged from 24 weeks to 10 years (*table 2*).

Flow diagram

(*figure 1*).

Sample size, gender, age and study origin

Of our twenty-two studies, ten studies were in Europe(29-38) and twelve from outside of Europe(39-50). We included a total of 4,834 participants (3,788 (78.4%) males). Four studies included males only(30, 34, 45, 47) and one study included women only(51). Participants mean age was 59.5 years. The mean age for individual studies ranged from 47.5 to 76.9 years (*table 2*).

Incomplete outcome data

The majority of trials (18/22; 82%) reported complete follow-up data, regardless of participants who were lost to follow-up or who dropped out. In four studies, outcome data were incomplete for 75 (75/4,834; 1.6%) participants with no description of withdrawal or drop-out(41, 47, 48, 50).

Participant diagnosis of coronary artery disease and treatment received

The diagnosis of participants recruited to the studies was described in the majority of studies (21/22; 95%). Thirteen studies enrolled participants with mixed diagnoses, including angina pectoralis

1 or coronary artery disease defined by angiography, myocardial infarction, percutaneous coronary
2 interventions or coronary artery bypass grafts(32, 36-42, 44, 46-48, 50). Six studies enrolled
3 participants following acute myocardial infarction only(29, 31, 33, 34, 43, 49) and two studies enrolled
4 participants diagnosed with angina pectoralis (unstable and stable angina) only(30, 35). It was unclear
5 from one study whether participants following myocardial infarction were included and instead, the
6 population was defined as 'patients after coronary artery bypass graft surgery'(45) (*table 2*).

7
8
9 Six studies recruited participants following percutaneous coronary intervention only(30, 32, 33,
10 35, 41, 46) and one study recruited participants following coronary artery bypass grafting only(45).
11 Twelve studies included participants who had received thrombolysis, percutaneous coronary
12 intervention, coronary artery bypass grafting and/or no revascularization procedure(31, 36-40, 42-44,
13 47, 48, 50). Three studies did not provide any breakdown of coronary intervention or surgical procedure
14 received by participants prior to enrollment(29, 34, 49) (*table 2*).

15 16 17 18 19 **Medication**

20
21 A full description and breakdown of the medication received by the participants, comparable to
22 optimal secondary prevention medical therapy defined by the Joint British recommendations on
23 prevention of Coronary Heart Disease in Clinical Practice set in 1998(24), was provided by 13/22 studies
24 (59%)(30-33, 35-40, 43, 49, 50). References to co-existing medical therapies were made in 7/22 (32%),
25 but no breakdowns were provided(29, 34, 41, 42, 45-47). One study referred to the prescription of anti-
26 hypertensive and hypolipidemic medications without reference to other recommended medications(48).
27 One study failed to provide any description or breakdown of co-existing medical therapies(44) (*table 2*).

28 29 30 31 32 **Clearly defined recruitment period**

33
34
35 Seven studies (7/22; 32%) were explicit that they recruited participants after the year 2000(36,
36 38, 42, 44-46, 49). In three studies, participants were recruited either just before or during the year
37 2000(30, 31, 41). Due to participant diagnosis, treatment received and co-existing medical therapies, it
38 was agreed by all reviewers to include these studies.

39
40 The remaining twelve studies failed to provide a recruitment period. Following further
41 examination of the full papers, due to adequate description of patient diagnosis, treatment received and
42 co-existing medical therapies, it was agreed by all reviewers to include these studies (*table 2*).

43 44 45 46 **Content of the interventions**

47
48 The content of the interventions tested was heterogeneous with multiple approaches being
49 adopted. Sixteen studies (16/22; 73%) compared exercise in combination with other therapies
50 (education, psychosocial management), whilst six studies compared exercise as a stand-alone
51 intervention, against a no exercise control. The exercise component alone varied considerably with
52 respect to setting, training modality, duration, session length, frequency and intensity (*table 3*).

53 54 55 56 **Overall effects of interventions**

All-cause mortality

Nineteen studies (n=4,194 participants) reported all-cause mortality (*figure 2*). There was no difference between groups at their longest follow-up (risk difference = 0.00, 95% CI -0.02 to 0.01, p=0.38). There was no evidence of statistical heterogeneity across trials (P value=0.91, I²=0%).

(*figure 2*).

Cardiovascular mortality

Nine studies (n = 1,182 participants) reported cardiovascular mortality (*figure 3*). There was no difference between groups at their longest follow-up (risk difference = -0.01, 95% CI -0.02 to 0.01, p=0.25). There was no evidence of statistical heterogeneity across trials (P value=0.44, I²=0%).

(*figure 3*).

Hospital admissions

Eleven studies (n= 1,768 participants) reported on proportion with one or more hospital admissions (*figure 4*). There was a reduction of borderline statistical significance (risk difference = -0.05, 95% CI -0.10 to -0.00, p=0.05). There was evidence of statistical heterogeneity across trials (P value=0.002, I²=64%).

(*figure 4*).

Discussion

The effectiveness of exercise-based CR in patients with coronary artery disease has been determined by Cochrane systematic reviews and meta-analyses, providing clinicians and academics with the highest level of evidence over the last 17 years(10, 52, 53). The latest Cochrane review, conducted in 2016, found benefits of exercise-based CR in terms of reduced cardiovascular mortality and hospital admissions, but unlike previous Cochrane reviews, found no effect on all-cause mortality(10). We identified that data from studies included in this review dated back as far as 1975(54). By including such historical data, this Cochrane review may not be correctly assessing the potential effect of contemporary exercise-based CR.

The current review aimed to assess the effect of exercise-based CR in the era of improved reperfusion strategies and simultaneous advances in pharmacological management, by only including studies whose participants were recruited after the year 2000. The majority of interventions tested in the twenty-two included trials (*table 3*) delivered an intervention recognised as best practice in exercise-based CR, where multiple approaches, including educational/psychosocial components, as well as the

1 exercise component were used(2, 3, 8). The interventions were tested against a no exercise control
2 consisting of educational and psychosocial components alone (*table 3*).

3
4 The current analyses demonstrated no improvement in all-cause mortality from participation in
5 exercise-based CR: the risk difference was 0.00 (95% CI -0.02 to 0.01). The largest trial included in our
6 analysis, the UK-based Rehabilitation after myocardial infarction trial (RAMIT) trial, sought to show a
7 20% reduction in relative risk based on an 11% mortality; i.e. a 2.2% risk difference(24). The limits of the
8 95% confidence interval for the effect size in our analysis do not include the RAMIT trial's pre-specified
9 clinically important difference. We therefore conclude that it is extremely unlikely that there is a
10 worthwhile benefit from exercise-based CR on all-cause mortality. Furthermore, it is unlikely that future
11 trials of similar interventions and populations, will change this conclusion. This is supported by a recent
12 meta-analysis which included participants with other forms of atherosclerotic cardiovascular disease i.e.
13 peripheral artery disease, ischaemic cerebrovascular accidents, diabetes and hypertension. They too
14 found a zero effect on all-cause mortality (relative risk 1.00, 95% CI 0.88 to 1.14)(55). With the mean
15 follow-up period for all studies included in our review being 24.7 months, it may be that any benefits on
16 mortality will accrue over a longer follow-up. However, the absence of any kind of signal in this review
17 means a substantial longer-term benefit is unlikely.

18
19 The current analyses do not quite exclude a worthwhile benefit of exercise-based CR on hospital
20 admissions. Whilst a risk difference of -0.05 (95% CI -0.10 to -0.00) is of borderline statistical
21 significance, it is probably clinically unimportant in the context of no change in all-cause mortality.

22
23 From the studies included in this review, we do not know if there is a worthwhile benefit on
24 quality of life, as a meta-analysis was not conducted. However, the authors of the 2016 Cochrane review
25 reported that in four of the twenty-two studies included in this review, there was a significantly higher
26 quality of life in at least half or more of the sub-scales(32, 45, 46, 49).

27
28 Based on the present data, we are also unable to comment on whether exercise-based CR might
29 be cost-effective. Five of the studies in this review included a within trial health economic evaluation(30,
30 40, 43, 44, 50). Of these five papers, three studies showed no difference in healthcare costs between
31 groups(40, 43, 50), one found healthcare costs to be lower for exercise-based CR(30), and one failed to
32 report a p-value for cost difference(44). Whilst a decrease, of borderline statistical significance, in
33 hospital admissions may improve quality of life for patients, it is unclear if this confers any economic
34 benefit, in the absence of robust cost-effectiveness analyses.

35
36 It may be that exercise-based CR has an effect on other outcomes, not specifically addressed in
37 this review, such as cardiorespiratory fitness, lifestyle risk factor management, adherence to medication,
38 diet, smoking cessation, psychosocial health and return to work(7, 8, 56, 57). If the focus of future
39 research is on measuring and improving these outcomes, attention will be needed to develop the best
40 multi-component intervention.

41 ***Strengths and Limitations***

42
43 To our knowledge, this is the first systematic review of exercise-based CR that has pooled data
44 relevant to contemporary medical management of patients diagnosed with coronary artery disease.
45 Although we have not done a de novo quality assessment of 21/22 studies included in this review and
46

1 instead are relying on a previous Cochrane assessment, it is unlikely that we would have drawn different
2 conclusions from such an assessment(10).
3

4 The current review does not provide information on participant baseline characteristics. In the
5 majority of studies (20/22; 91%), however, baseline characteristics were comparable between the
6 intervention and control groups(10, 29).
7

8 Whilst there was no evidence of statistical heterogeneity across trials for all outcome measures
9 (P value<0.01, I²>30%), except for hospital admissions, there was substantial context and interventional
10 heterogeneity. The studies came from a wide range of clinical environments and countries, and the
11 interventions delivered ranged greatly in quality. When compared with both the BACPR ‘minimum
12 standards and core components’(8) and ACPICR guidelines(6), there was considerable variation in the
13 exercise interventions delivered (*table 3*). Critics have questioned the exercise component reported in
14 the largest included study, the RAMIT trial (n=1813)(31). They argued that under-dosage of exercise
15 intensity and duration may have led to the inconclusive result(58). Several other studies included in this
16 review also fail to report on the intensity, modality and/or duration of the exercise intervention. Exercise
17 and physical activity has a ‘dose-response’ relationship with cardiovascular disease risk(59). Moreover, a
18 higher exercise capacity (VO₂ peak) is associated with an improvement in mortality risk(60, 61). If
19 patients engaging in exercise-based CR do not achieve the correct dose of exercise, a physiological
20 benefit is unlikely. It is a legitimate concern that participants in many included trials may not have
21 received an adequate dose of exercise. In the era of contemporary medical management, higher intensity
22 exercise protocols might be appropriate and effective(62).
23
24
25
26
27

28 One major concern is the reporting of adherence to, and fidelity of, exercise interventions(10).
29 Whilst the majority of studies included in this review report the intended prescription exercise dose(29,
30 30, 32-37, 39, 40, 47, 50) (*table 3*), it is not possible to determine adherence and fidelity. Without basic
31 reporting of these parameters, the actual exercise dose received cannot be quantified. This may have a
32 significant bearing on intervention efficacy and the results of this meta-analysis. Moving forward, the
33 introduction of checklists and reporting standards of interventional studies should improve reporting
34 quality and trial interpretation(63).
35
36
37
38

39 **Conclusion**

40
41 Based on the outcomes of all-cause mortality and cardiovascular mortality, our analysis
42 indicates conclusively that the current approach to exercise-based CR has no effect when compared to a
43 no exercise control. There may be a small reduction in hospital admissions following exercise-based CR
44 that is unlikely to be clinically important.
45
46

47 The continued delivery of exercise-based CR needs to be supported by new research to show its
48 impact on health-related quality of life and whether it is a cost-effective intervention.
49
50

51 **Contributors**

52
53 RP and MU were principally responsible for the study concept and design. RP and GM were
54 responsible for study selection, data extraction and risk of bias assessment. With the assistance of
55 University Hospital Coventry & Warwickshire library services, RP updated and ran the searches. RP, MU
56
57

1 and PK were responsible for statistical analysis and interpretation of data. GM and SE provided clinical
2 advice. RP and MU wrote the first draft of the review and all co-authors contributed to review and
3 editing of drafts of the report. All authors approved the final manuscript. RP is the study guarantor and
4 had full access to all trial level data in the review, takes responsibility for the integrity of the data, and
5 accuracy of the data analysis, and had final responsibility to submit for publication.
6
7

8 9 **Copyright**

10
11 The Corresponding Author has the right to grant on behalf of all authors and does grant on
12 behalf of all *authors*, a worldwide license to the Publishers and its licensees in perpetuity, in all forms,
13 formats and media (whether known now or created in the future), to i) publish, reproduce, distribute,
14 display and store the Contribution, ii) translate the Contribution into other languages, create
15 adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the
16 Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all
17 subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third
18 party material where-ever it may be located; and, vi) license any third party to do any or all of the above.
19
20
21
22

23 24 **Funding**

25
26 This review was not funded and hence no role was played by funders in the conception, data
27 synthesis, analysis, interpretation or in the drafting of the manuscript.
28
29

30 31 **Competing interests**

32
33 All authors have completed the *Unified Competing Interest form* (available on request from the
34 corresponding author) and declare: no support from any organisation for the submitted work; no
35 financial relationships with any organisations that might have an interest in the submitted work in the
36 previous three years, no other relationships or activities that could appear to have influenced the
37 submitted work.
38
39
40

41 42 **Ethical Approval**

43
44 Ethical approval not required.
45

46 47 **Data sharing**

48
49 No additional data available.
50

51
52 The lead author (RP) affirms that the manuscript is an honest, accurate, and transparent
53 account of the study being reported; that no important aspects of the study have been omitted; and that
54 any discrepancies from the study as planned and registered have been explained.
55
56
57

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Tables

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Table 1. Risk of bias assessment for additional study

7 Santaularia *et al.* 2017

| Bias | Authors' judgement | Support for judgement |
|--------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Random sequence generation (selection bias) | Low risk | A randomisation list in blocks of ten was created by a computer random number generator. The randomisation list and the allocation of patients to each group were independently controlled by the Clinical Trials Unit.' |
| Allocation concealment (selection bias) | Low risk | A randomisation list in blocks of ten was created by a computer random number generator. The randomisation list and the allocation of patients to each group were independently controlled by the Clinical Trials Unit.' |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk | An independent committee that was blind to the patients' treatment group assessed the main outcomes. This committee comprised a cardiologist, a rehabilitation cardiologist and a health information manager, all from different centres.' |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | There was no loss to follow-up. |
| Selective reporting (reporting bias) | Low risk | All outcomes described in the methods were reported in the results. Results regarding quality of life are presented in supplementary data but were not required for the current review. |
| Groups balanced at baseline | Low risk | No significant differences between groups were observed, with the exception of gender: 23% of the control group were women compared with 7% in the intervention group ($p=0.049$). |
| Intention-to-treat analysis conducted | High risk | No analysis was conducted. |
| Groups received same treatment (apart from the intervention) | Low risk | Patients assigned to the control group received standard care given at the hospital'. In addition to standard care, patients randomised to the intervention group....'. |

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Overview of participants, recruitment period, patient diagnosis and medical therapy

| Reference s, country | N | Mean age (year s) | Male participan ts (%) | Recruitme nt period (years) | Maximu m follow- up period | Patient diagnosis | Medication |
|----------------------------------------|-----|----------------------------|------------------------------|-----------------------------------|----------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aronov <i>et al.</i> (2010), Russia | 392 | 61.4 | 73.5 | None specified | 1 year | AMI, stable angina, unstable angina or myocardial revascularisation. | Standard medical therapy- β -blocker, acetylsalicylic acid or other antithrombotic drug, nitrate, ACE inhibitor. Some patients on lipid- lowering drugs. |

| | | | | | | | | | | | |
|----|------------------------|-----|------|------|--------------|--|--|--|-----------|------------------------|------------------------------------------|
| 1 | | | | | | | | | | | |
| 2 | | | | | | | | | | | |
| 3 | | | | | | | | | | | |
| 4 | Belardinelli | | | | | | | | 33 | CAD including AMI. | According to international |
| 5 | <i>et al.</i> | | | | | | | | months | Successful PCI in 1 or | accepted protocols- |
| 6 | (2001), | 118 | 61 | 100 | None | | | | | 2 native epicardial | aspirin, ticlopidine, |
| 7 | Italy | | | | specified | | | | | coronary arteries | calcium antagonists, |
| 8 | | | | | | | | | | only. | nitrates. |
| 9 | | | | | | | | | 1 year | Uncomplicated AMI | Aspirin, antiarrhythmic |
| 10 | Briffa <i>et al.</i> | | | | | | | | | or recovery from | agent, β -blocker, ACE |
| 11 | (2005), | 113 | 47.5 | 89.5 | None | | | | | unstable angina. PCI, | inhibitor, calcium |
| 12 | Australia | | | | specified. | | | | | CABG, thrombolytic | antagonist, long acting |
| 13 | | | | | | | | | | therapy. | nitrate, diuretic. |
| 14 | Giallauria | | | | | | | | 6 months | AMI and undergone | Aspirin, β -blocker, ACE |
| 15 | <i>et al.</i> | | | | | | | | | primary or rescue | inhibitor, ARB, statin. |
| 16 | (2008), | 61 | 58.5 | 78.5 | None | | | | | PCI only. | |
| 17 | Italy | | | | specified. | | | | | | |
| 18 | Hambrech | | | | | | | | 1 year | Stable CAD defined | β -receptor antagonists, β - |
| 19 | <i>et al.</i> | | | | | | | | | by angina pectoralis | HMG-CoA reductase |
| 20 | (2004), | 101 | 56 | 87.3 | 1997-2001 | | | | | and amenable to PCI. | inhibitors, ACE inhibitor, |
| 21 | Germany | | | | | | | | | AMI patients | acetylsalicylic acid. |
| 22 | | | | | | | | | | excluded. | |
| 23 | Higgins <i>et al.</i> | | | | | | | | 51 weeks | Post-PCI patients | Reference to medical |
| 24 | (2001), | 105 | 60.8 | 81.3 | 1995-1997 | | | | | only. No AMI 1 | therapy, only breakdown |
| 25 | Australia | | | | | | | | | month pre- | for lipid lowering |
| 26 | | | | | | | | | | procedure. | medication. |
| 27 | | | | | | | | | 12 months | Patients hospitalised | |
| 28 | | | | | | | | | | for an ACS (unstable | |
| 29 | Houle <i>et al.</i> | | | | | | | | | angina, non-ST- | |
| 30 | (2012), | 65 | 51.5 | 100 | 2007-2008 | | | | | elevation or ST | Reference to medication in |
| 31 | Canada | | | | | | | | | elevation MI). PCI, | usual care group, but no |
| 32 | | | | | | | | | | CABG or no | breakdown. |
| 33 | | | | | | | | | | revascularisation | |
| 34 | | | | | | | | | | procedure. | |
| 35 | Kovoor <i>et al.</i> | | | | | | | | 6 months | AMI only. | Aspirin, β -blocker, ACE |
| 36 | (2006), | 142 | 51.5 | 100 | None | | | | | Thrombolytic | inhibitor, calcium channel |
| 37 | Australia | | | | specified. | | | | | therapy, one patient | blockers, nitrates, |
| 38 | | | | | | | | | | in the exercise | cholesterol-lowering |
| 39 | | | | | | | | | | treatment group had | agents, |
| 40 | | | | | | | | | | primary angioplasty. | |
| 41 | Maddison | | | | | | | | 24 weeks | Diagnosis of IHD | No description. |
| 42 | <i>et al.</i> | | | | | | | | | (angina, MI, | |
| 43 | (2014), | 171 | 59 | 20 | 2010-2012 | | | | | revascularisation, | |
| 44 | New | | | | | | | | | including | |
| 45 | Zealand | | | | | | | | | angioplasty, stent, or | |
| 46 | | | | | | | | | | CABG). | |
| 47 | | | | | | | | | | | |
| 48 | | | | | | | | | | | |
| 49 | | | | | | | | | | | |
| 50 | | | | | | | | | 10 years | | Medication regimens |
| 51 | Maroto <i>et al.</i> | | | | (None | | | | | | employed in secondary |
| 52 | (2005), | 180 | 76.9 | 57.5 | specified) 2 | | | | | | prevention at discharge |
| 53 | Spain | | | | year | | | | | | were clearly insufficient by |
| 54 | | | | | enrollment | | | | | | standard criteria but |
| 55 | | | | | period. | | | | | | currently meet Spanish |
| 56 | | | | | | | | | | | and European guidelines'. |
| 57 | | | | | | | | | | | |
| 58 | | | | | | | | | | | |
| 59 | | | | | | | | | | | |
| 60 | | | | | | | | | | | |
| | Munk <i>et al.</i> | | | | | | | | 6 months | Stable angina and | Aspirin, β -blocker, ACE |
| | (2009), | 40 | 56.4 | 84.8 | None | | | | | unstable angina, post | inhibitor, ARB, statin, |
| | Norway | | | | specified. | | | | | PCI only. AMI | acetylsalicylic acid. |
| | | | | | | | | | | patients excluded. | |
| | | | | | | | | | | | |
| | Mutwalli <i>et al.</i> | | | | | | | | 6 months | Undergone CABG | Participants received |
| | (2012), | 49 | 69.7 | 100 | 2008-2010 | | | | | surgery. Unknown | advice that focused on |
| | Saudi | | | | | | | | | whether AMI | medications', no |
| | Arabia | | | | | | | | | patients included. | breakdown. |

| | | | | | | | | |
|----|-----------------------------------------|-----|------|------|-----------------|--------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| 1 | | | | | | 12 months (mortality data after 5.5 years) | Recent coronary event defined as AMI, PCI, CABG or without invasive procedure. | β -blocker, antithrombotics, calcium antagonists, lipid-lowering agents, diuretics. |
| 2 | Oerkild <i>et al.</i> (2012), Denmark | 40 | 63.5 | 0 | 2007-2008 | | | |
| 3 | | | | | | | | |
| 4 | | | | | | | | |
| 5 | | | | | | | | |
| 6 | Reid <i>et al.</i> (2012), Canada | 223 | 54.5 | 87.3 | 2004-2007 | 12 months | ACS including AMI, underwent successful PCI only. | Reference to a 'descriptive summary in supplemental table', no access. |
| 7 | | | | | | | | |
| 8 | | | | | | | | |
| 9 | | | | | | | | |
| 10 | Santaularia <i>et al.</i> (2017), Spain | 85 | 59.6 | 84.7 | None specified. | 12 months | AMI only, no evidence of revascularisation procedure. | Reference to cardiac medication, but no breakdown |
| 11 | | | | | | | | |
| 12 | | | | | | | | |
| 13 | | | | | | | | |
| 14 | Seki <i>et al.</i> (2008), Japan | 39 | 57.8 | 83.8 | None specified. | NR | AMI, PCI or CABG. | Reference to 'lipid-lowering drugs and other medications', no breakdown. |
| 15 | | | | | | | | |
| 16 | | | | | | | | |
| 17 | | | | | | | | |
| 18 | Toobert <i>et al.</i> (2000), USA | 25 | 64.5 | 0 | None specified. | 24 months | CAD defined as atherosclerosis, AMI, PCI or CABG. | Anti-hypertensive and hypolipidemic medications. |
| 19 | | | | | | | | |
| 20 | | | | | | | | |
| 21 | VHSG <i>et al.</i> (2003), Norway | 197 | 64 | 75.8 | None specified. | 2 years | AMI, unstable angina pectoris or after PCI or CABG. | Aspirin, β -blocker, statin, ACE inhibitor, calcium antagonist, warfarin. |
| 22 | | | | | | | | |
| 23 | | | | | | | | |
| 24 | | | | | | | | |
| 25 | Wang <i>et al.</i> (2012), China | 160 | 67 | 63.5 | 2005-2007 | 6 months | AMI only. | Anti-platelet, Nitrate, β -blocker, ACE inhibitor, calcium antagonist, statin. |
| 26 | | | | | | | | |
| 27 | | | | | | | | |
| 28 | | | | | | | | |
| 29 | | | | | | | | |
| 30 | West <i>et al.</i> (2012), UK | 181 | 51.9 | 93.9 | 1997-2000 | 7 to 9 years | AMI only. | Aspirin, β -blocker, ACE inhibitor, diuretic, long acting nitrate/ calcium channel blocker, statin, GTN. |
| 31 | | | | | | | | |
| 32 | | | | | | | | |
| 33 | | | | | | | | |
| 34 | Yu <i>et al.</i> (2004), China | 269 | 56 | 83.9 | None specified. | 2 years | Recent AMI, after elective PCI or thrombolytic therapy. | Anti-platelet, β -blocker, calcium channel blocker, nitrate, statin, ACE inhibitor, diuretic. |
| 35 | | | | | | | | |
| 36 | | | | | | | | |
| 37 | | | | | | | | |
| 38 | | | | | | | | |
| 39 | Zwisler <i>et al.</i> (2008), Denmark | 446 | 55.5 | 72.1 | 2000-2003 | 1 year | AMI, angina pectoris or after PCI or CABG. | Antithrombotics, lipid-lowering drugs, β -blocker, calcium antagonists, ACE inhibitor, diuretic, long-acting nitrates. |
| 40 | | | | | | | | |

AMI- Acute Myocardial Infarction, CAD- Coronary Artery Disease, PCI- Percutaneous Coronary Intervention, IHD- Ischaemic Heart Disease, CABG- Coronary Artery Bypass Graft, CHD- Coronary Heart Disease, ACS- Acute Coronary Syndrome, ACE- Angiotensin-Converting-Enzyme, ARB- Angiotensin Receptor Blockers, GTN- Glyceryl Trinitrate.

Table 3. Overview of exercise interventions

| References, country | Exercise Intervention | | Study Duration | Session Duration/Frequency/Intensity | Additional | Control (comparator) |
|-------------------------------------|---------------------------------------------------------|------------------|----------------|-----------------------------------------------------------------------------------------------------|-----------------|---------------------------|
| | Exercise | Modality | | | | |
| Aronov <i>et al.</i> (2010), Russia | Moderate intensity physical training (unknown setting). | Cycle ergometer. | 12 months | 45 minutes- 60 minutes/ 3 sessions per week/ 50-60% of the performed capacity by bicycle ergometry. | None specified. | Standard medical therapy. |

| | | | | | | | |
|----|-----------------------|--------------------|------------|-----------|--------------------------------|-------------|----------------|
| 1 | | | | | | | Recommended |
| 2 | | | | | | | to perform |
| 3 | | | | | | | basic daily |
| 4 | Belardinelli | Moderate intensity | | | | | mild physical |
| 5 | <i>et al.</i> | exercise | | 6 | 53 minutes/ 3 sessions per | | activities but |
| 6 | (2001), | (supervised in | Cycle | months | week/ 60% of peak oxygen | None | to avoid any |
| 7 | Italy | hospital gym). | ergometer. | | uptake (VO ₂ Peak). | specified. | physical |
| 8 | | | | | | | training. |
| 9 | | | | | | Education | Education, |
| 10 | | | | | | and | pharmacother |
| 11 | Briffa <i>et al.</i> | Aerobic circuit | Aerobic | 6 weeks | 60-90 minutes/ 3 sessions per | Education | apy and |
| 12 | (2005), | training | circuit | | week/ not specified. | and | lifestyle |
| 13 | Australia | (supervised in | training. | | | counselling | counselling. |
| 14 | | | | | | | |
| 15 | | | | | | | Generic |
| 16 | | | | | | | instructions |
| 17 | Giallauria | Moderate intensity | | | | | on |
| 18 | <i>et al.</i> | exercise | | | | | maintaining |
| 19 | (2008), | (supervised in | Cycle | 6 | 40 minutes/ 3 sessions per | None | physical |
| 20 | Italy | centre). | ergometer. | months | week/ 60%-70% of peak | specified. | activity and a |
| 21 | | | | | | | correct |
| 22 | | | | | | | lifestyle. |
| 23 | Hambrecht | Moderate intensity | | | | | Standard |
| 24 | <i>et al.</i> | exercise | | | | | medical |
| 25 | (2004), | (supervised in | | | | | therapy. |
| 26 | Germany | hospital & | Cycle | 12 | 10 minutes- 42 sessions per | None | |
| 27 | | unsupervised at | ergometer. | months | week (hospital), 20 minutes- 7 | specified. | |
| 28 | | home). | | | sessions per week (home) plus | | |
| 29 | | | | | 60 minutes' group training- 1 | | |
| 30 | | | | | session per week/ 70% of | | |
| 31 | | | | | symptom-limited max HR. | | |
| 32 | | | | | | | |
| 33 | | | | | | | |
| 34 | Higgins <i>et al.</i> | Moderate intensity | | | | Psychologi | Psychological |
| 35 | (2001), | walking | | | | cal plus | support, |
| 36 | Australia | programme | Walking. | Not | Not specified/ not specified/ | education. | education, |
| 37 | | (unsupervised at | | specified | not specified. | | counselling |
| 38 | | home). | | . | | | and guidance. |
| 39 | | | | | | | |
| 40 | | | | | | | |
| 41 | | | | | | | |
| 42 | | | | | | | |
| 43 | | | | | | | |
| 44 | | | | | | | |
| 45 | | | | | | | |
| 46 | | | | | | | |
| 47 | | | | | | | |
| 48 | | | | | | | |
| 49 | | | | | | | |
| 50 | | | | | | | |
| 51 | | | | | | | |
| 52 | | | | | | | |
| 53 | | | | | | | |
| 54 | | | | | | | |
| 55 | | | | | | | |
| 56 | | | | | | | |
| 57 | | | | | | | |
| 58 | | | | | | | |
| 59 | | | | | | | |
| 60 | | | | | | | |

| | | | | | | | |
|----|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------|--------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | Moderate/high intensity interval training (supervised in centre). | Cycle ergometer or running. | 6 months | 60 minutes/ 3 sessions per week/ 60-70% & 80-90% max HR. | Spine & abdominal resistance training. | Usual care, including drug therapy. |
| 5 | Munk <i>et al.</i> (2009), Norway | | | | | | |
| 6 | | Moderate intensity walking programme (unsupervised at home). | Walking. | 6 months | 30 minutes/ 7 sessions per week/ not specified. | Education. | Education, standard hospital care. |
| 7 | | | | | | | |
| 8 | | | | | | | |
| 9 | Mutwalli <i>et al.</i> (2012), Saudi Arabia | | | | | | |
| 10 | | Moderate intensity exercise (unsupervised at home). | Individualised | 12 months | 30 minutes/ 6 sessions per week/ 11-13 on the Borg Scale. | Risk factor management. | Usual care, no exercise education or dietary counselling. |
| 11 | Oerkild <i>et al.</i> (2012), Denmark | | | | | | |
| 12 | | Internet based physical activity plan and motivational tool to increase physical activity (unsupervised at home). | Not specified. | 20 weeks | Not specified/ not specified/ not specified. | None specified. | Online education, physical activity guidance and an education booklet. |
| 13 | | | | | | | |
| 14 | | | | | | | |
| 15 | | | | | | | |
| 16 | | | | | | | |
| 17 | | | | | | | |
| 18 | | | | | | | |
| 19 | | | | | | | |
| 20 | | | | | | | |
| 21 | Reid <i>et al.</i> (2012), Canada | | | | | | |
| 22 | | | | | | | |
| 23 | | | | | | | |
| 24 | | | | | | | |
| 25 | | | | | | | |
| 26 | | | | | | | |
| 27 | | | | | | | |
| 28 | | | | | | | |
| 29 | Santaularia <i>et al.</i> (2017), Spain | Outpatient exercise training programme (supervised in hospital). | Cycle ergometer | 10 weeks | 60 minutes/ 3 sessions per week/ 75-90% max HR (RPE 11-15 on Borg Scale) | Resistance training, education and risk factor management. | Standard care, risk factor management, guidance on physical activity and adherence to medication. |
| 30 | | | | | | | |
| 31 | | | | | | | |
| 32 | | | | | | | |
| 33 | | | | | | | |
| 34 | | | | | | | |
| 35 | | | | | | | |
| 36 | | | | | | | |
| 37 | | | | | | | |
| 38 | | | | | | | |
| 39 | | | | | | | |
| 40 | | | | | | | |
| 41 | | | | | | | |
| 42 | | | | | | | |
| 43 | | | | | | | |
| 44 | | | | | | | |
| 45 | | | | | | | |
| 46 | | | | | | | |
| 47 | | | | | | | |
| 48 | | | | | | | |
| 49 | | | | | | | |
| 50 | | | | | | | |
| 51 | | | | | | | |
| 52 | | | | | | | |
| 53 | | | | | | | |
| 54 | | | | | | | |
| 55 | | | | | | | |
| 56 | | | | | | | |
| 57 | | | | | | | |
| 58 | | | | | | | |
| 59 | | | | | | | |
| 60 | | | | | | | |

| | | | | | | | |
|----|---------------------------------------|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|
| 1 | | Ambulatory and aerobic cardiovascular training (supervised in hospital and centre, unsupervised at home). | Walking, treadmill, cycle ergometry, rowing, stepper, arm ergometry, dumbbell. | 8 1/2 months | 2 hours/ 2 sessions per week (centre), not specified (home)/ 65-85% of maximal aerobic capacity (VO ₂ Peak). | Resistance training and education. | Conventional medical therapy and education. |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | | | | | | |
| 5 | | | | | | | |
| 6 | Yu <i>et al.</i> (2004), China | | | | | | |
| 7 | | | | | | | |
| 8 | | | | | | | |
| 9 | | Intensive CR programme (supervised in centre). | Not specified. | 6 weeks | Not specified/ 2 sessions per week/ not specified. | Education and psychosocial support. | Education and psychosocial support. |
| 10 | Zwisler <i>et al.</i> (2008), Denmark | | | | | | |
| 11 | | | | | | | |
| 12 | | | | | | | |

HR- Heart Rate, VO₂ Peak- Peak Oxygen Uptake

References

- World Health Organisation. Top 10 causes of death worldwide- Fact Sheet 2017 29/05/2017. Available from: <http://www.who.int/mediacentre/factsheets/fs310/en/>.
- NICE. Myocardial Infarction: cardiac rehabilitation and prevention of further cardiovascular disease 2013 31/05/2017. Available from: <https://www.nice.org.uk/guidance/cg172/resources/myocardial-infarction-cardiac-rehabilitation-and-prevention-of-further-cardiovascular-disease-pdf-35109748874437>.
- BACPR. Cardiovascular Disease Prevention and Rehabilitation 2012 31/05/2017. Available from: http://www.bacpr.com/resources/46C_BACPR_Standards_and_Core_Components_2012.pdf.
- Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. *Eur J Prev Cardiol.* 2014;21(6):664-81.
- Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. *J Cardiopulm Rehabil Prev.* 2007;27(3):121-9.
- ACPICR. Standards for Physical Activity and Exercise in the Cardiovascular Population 2015 31/05/2017. Available from: http://acpicr.com/sites/default/files/ACPICR_Standards_2015.pdf.
- Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. *BMJ.* 2015;351:h5000.
- Buckley JP, Furze G, Doherty P, Speck L, Connolly S, Hinton S, et al. BACPR scientific statement: British standards and core components for cardiovascular disease prevention and rehabilitation. *Heart.* 2013;99(15):1069-71.
- Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. *BMJ.* 2010;340:b5631.
- Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. *J Am Coll Cardiol.* 2016;67(1):1-12.
- Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet.* 2003;361(9351):13-20.
- D'Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary angioplasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis. *Eur Heart J.* 2011;32(8):972-82.
- Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J.* 2003;24(1):28-66.
- West RM, Cattle BA, Bouyssié M, Squire I, de Belder M, Fox KA, et al. Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. *Eur Heart J.* 2011;32(6):706-11.

15. Anon. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Multicentre international study: supplementary report. *Br Med J.* 1977;2(6084):419-21.
16. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. *Br Med J.* 1974;1(5905):436-40.
17. Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344(8934):1383-9.
18. Anon. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. *Circulation.* 1998;97(22):2202-12.
19. Skinner JS, Minhas R. Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction. *Heart.* 2007;93(7):864-6.
20. Eisen A, Bhatt DL. Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. *Heart.* 2016.
21. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. *Curr Probl Cardiol.* 2010;35(2):72-115.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *Open Med.* 2009;3(3):e123-30.
23. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J.* 1996;17(1):43-63.
24. Wood DA DP, Poutler N, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. *Heart.* 1998;80 Suppl 2:S1-29.
25. RevMan. The Nordic Cochrane Centre: The Cochrane Collaboration, version 5.3 (Review Manager)2014.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327(7414):557-60.
27. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
28. Kadda O, Kotanidou A, Manginas A, Stavridis G, Nanas S, Panagiotakos DB. Lifestyle intervention and one-year prognosis of patients following open heart surgery: a randomised clinical trial. *Journal of Clinical Nursing.* 2015;24(11-12):1611-21.
29. Santaularia N, Caminal J, Arnau A, Perramon M, Montesinos J, Abenoza Guardiola M, et al. The efficacy of a supervised exercise training programme on readmission rates in patients with myocardial ischemia: Results from a randomised controlled trial. *European Journal of Cardiovascular Nursing.* 2017;16(3):201-12.
30. Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation.* 2004;109(11):1371-8.
31. West RR, Jones DA, Henderson AH. Rehabilitation after myocardial infarction (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. *Heart.* 2012;98(8):637-44.
32. Belardinelli R, Paolini I, Cianci G, Piva R, Georgiou D, Purcaro A. Exercise training intervention after coronary angioplasty: the ETICA trial. *J Am Coll Cardiol.* 2001;37(7):1891-900.
33. Giallauria F, Cirillo P, Lucci R, Pacileo M, De Lorenzo A, D'Agostino M, et al. Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. *Eur J Cardiovasc Prev Rehabil.* 2008;15(1):113-8.
34. Maroto JM, Artigao Ramírez R, Morales Durán MD, de Pablo Zarzosa C, Abaira V. [Cardiac rehabilitation in patients with myocardial infarction: a 10-year follow-up study]. *Rev Esp Cardiol.* 2005;58(10):1181-7.
35. Munk PS, Staal EM, Butt N, Isaksen K, Larsen AI. High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation A randomized controlled trial evaluating the relationship to endothelial function and inflammation. *Am Heart J.* 2009;158(5):734-41.
36. Oerkild B, Frederiksen M, Hansen JF, Prescott E. Home-based cardiac rehabilitation is an attractive alternative to no cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial. *BMJ Open.* 2012;2(6).
37. Vestfold Heartcare Study Group. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. *Eur J Cardiovasc Prev Rehabil.* 2003;10(6):429-37.
38. Zwisler AD, Soja AM, Rasmussen S, Frederiksen M, Abedini S, Abadini S, et al. Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart

- disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial. *Am Heart J*. 2008;155(6):1106-13.
39. Aronov DM, Krasnitskii VB, Bubnova MG, Pozdnyakov IM, Ioseliani DG, Shchegol'kov AN, et al. [Physical training at ambulatory-polyclinical stage in complex rehabilitation and secondary prevention of patients with ischemic heart disease after acute incidents. Effect on physical working capacity, hemodynamics, blood lipids, clinical course and prognosis (Russian cooperative study)]. *Kardiologiya*. 2009;49(3):49-56.
40. Briffa TG, Eckermann SD, Griffiths AD, Harris PJ, Heath MR, Freedman SB, et al. Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. *Med J Aust*. 2005;183(9):450-5.
41. Higgins HC, Hayes RL, McKenna KT. Rehabilitation outcomes following percutaneous coronary interventions (PCI). *Patient Educ Couns*. 2001;43(3):219-30.
42. Houle J, Doyon O, Vadeboncoeur N, Turbide G, Diaz A, Poirier P. Effectiveness of a pedometer-based program using a socio-cognitive intervention on physical activity and quality of life in a setting of cardiac rehabilitation. *Can J Cardiol*. 2012;28(1):27-32.
43. Kovoov P, Lee AK, Carrozzi F, Wiseman V, Byth K, Zecchin R, et al. Return to full normal activities including work at two weeks after acute myocardial infarction. *Am J Cardiol*. 2006;97(7):952-8.
44. Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr A, Jiang Y, et al. A mobile phone intervention increases physical activity in people with cardiovascular disease: Results from the HEART randomized controlled trial. *Eur J Prev Cardiol*. 2014;22(6):701-9.
45. Mutwalli HA, Fallows SJ, Arnous AA, Zamzami MS. Randomized controlled evaluation shows the effectiveness of a home-based cardiac rehabilitation program. *Saudi Med J*. 2012;33(2):152-9.
46. Reid RD, Morrin LI, Beaton LJ, Papadakis S, Kocourek J, McDonnell L, et al. Randomized trial of an internet-based computer-tailored expert system for physical activity in patients with heart disease. *Eur J Prev Cardiol*. 2012;19(6):1357-64.
47. Seki E, Watanabe Y, Shimada K, Sunayama S, Onishi T, Kawakami K, et al. Effects of a phase III cardiac rehabilitation program on physical status and lipid profiles in elderly patients with coronary artery disease: Juntendo Cardiac Rehabilitation Program (J-CARP). *Circ J*. 2008;72(8):1230-4.
48. Toobert DJ, Glasgow RE, Radcliffe JL. Physiologic and related behavioral outcomes from the Women's Lifestyle Heart Trial. *Ann Behav Med*. 2000;22(1):1-9.
49. Wang W, Chair SY, Thompson DR, Twinn SF. Effects of home-based rehabilitation on health-related quality of life and psychological status in Chinese patients recovering from acute myocardial infarction. *Heart Lung*. 2012;41(1):15-25.
50. Yu CM, Lau CP, Chau J, McGhee S, Kong SL, Cheung BM, et al. A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention. *Arch Phys Med Rehabil*. 2004;85(12):1915-22.
51. Toobert DJ, Strycker LA, Glasgow RE. Lifestyle change in women with coronary heart disease: what do we know? *J Womens Health*. 1998;7(6):685-99.
52. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. *Cochrane Database Syst Rev*. 2001(1):CD001800.
53. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev*. 2011(7):CD001800.
54. Wilhelmsen L, Sanne H, Elmfeldt D, Grimby G, Tibblin G, Wedel H. A controlled trial of physical training after myocardial infarction. Effects on risk factors, nonfatal reinfarction, and death. *Prev Med*. 1975;4(4):491-508.
55. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. *Int J Cardiol*. 2017;232:294-303.
56. Valkeinen H, Aaltonen S, Kujala UM. Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis. *Scand J Med Sci Sports*. 2010;20(4):545-55.
57. Yohannes AM, Doherty P, Bundy C, Yalfani A. The long-term benefits of cardiac rehabilitation on depression, anxiety, physical activity and quality of life. *J Clin Nurs*. 2010;19(19-20):2806-13.
58. Conraads VM, Denollet J, De Maeyer C, Van Craenenbroeck E, Verheyen J, Beckers P. Exercise training as an essential component of cardiac rehabilitation. *Heart*. 2012;98(8):674-5; author reply 5.
59. Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. *Circulation*. 2011;124(7):789-95.
60. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA*. 2009;301(19):2024-35.
61. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc*. 2011;43(7):1334-59.

1
2 62. McGregor G, Nichols S, Hamborg T, Bryning L, Tudor-Edwards R, Markland D, et al. High-intensity
3 interval training versus moderate-intensity steady-state training in UK cardiac rehabilitation programmes (HIIT or
4 MISS UK): study protocol for a multicentre randomised controlled trial and economic evaluation. *BMJ Open*.
2016;6(11):e012843.

5 63. Slade SC, Dionne CE, Underwood M, Buchbinder R, Beck B, Bennell K, et al. Consensus on Exercise
6 Reporting Template (CERT): Modified Delphi Study. *Phys Ther*. 2016;96(10):1514-24.

7 8 **Legends**

9 *Figure 1.* Summary of study selection process

10 *Figure 2.* All-cause mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual
11 studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95%
12 confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR-
13 Cardiac Rehabilitation.

14 *Figure 3.* Cardiovascular mortality for studies at their longest follow-up period. Filled squares represent the risk difference for
15 individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent
16 their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects
17 analysis. CR- Cardiac Rehabilitation.

18 *Figure 4.* Hospital admissions for studies at their longest follow-up period. Filled squares represent the risk difference for
19 individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent
20 their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects
21 analysis. CR- Cardiac Rehabilitation.




Figure 1. Summary of study selection process.

338x190mm (300 x 300 DPI)




Figure 2. All-cause mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)




Figure 3. Cardiovascular mortality for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)




Figure 4. Hospital admissions for studies at their longest follow-up period. Filled squares represent the risk difference for individual studies at the longest reported follow-up. The boxes are proportional to the weight of each study and the lines represent their 95% confidence interval (CI). The filled diamond represents the pooled risk difference. Weights are from random effects analysis. CR- Cardiac Rehabilitation.

209x278mm (300 x 300 DPI)

Appendix 1

Search Name: CENTRAL repeat search- limited 2014-2017

Last Saved: 28/02/2017 14:50:03.214

Description: 28/02/17

ID Search

#1 MeSH descriptor: [Myocardial Ischemia] explode all trees

#2 (myocard* near isch*mi*):ti,ab,kw

#3 isch*mi* near heart:ti,ab,kw

#4 MeSH descriptor: [Coronary Artery Bypass] explode all trees

#5 myocard* near infarct*:ti,ab,kw

#6 heart near infarct*:ti,ab,kw

#7 angina:ti,ab,kw

#8 coronary near (disease* or bypass or thrombo* or angioplast*):ti,ab,kw

#9 MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees

#10 (percutaneous next coronary near/2 (interven* or revascular*))

#11 MeSH descriptor: [Angioplasty] explode all trees

#12 angioplast*

#13 ((coronary or arterial) near/4 dilat*)

#14 endoluminal next repair*



PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 2 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4,5 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4/appendix 1 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4,5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 4,5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 6 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis. | 6 |



PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|-------------------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 5,6 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| RESULTS | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 7 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 12-17 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 6, 12,13 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 8,9 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 8,9/figures 2,3,4 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 8,9 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
| DISCUSSION | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 9,10 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 10,11 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 11 |
| FUNDING | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 12 |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.